Official source · cited records
PubMed, page 2
2,673 public records from PubMed that PeptideScanner profiles or records cite, newest check first. Inclusion is not a source rating, endorsement, or claim of comprehensive monitoring.
Page 2 of 6
Official source · 2,673 cited records
- Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients. · retained source version 1:2026-11-09:current:8b742cc3858bdb19be82d07b027d54cd0cff388a0fa3aee7c283818ad014854f ↗Source checked November 16, 2026
- Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition. · retained source version 1:2022-05-31:current:7cf186ddac43541739125c58b03e6f947b69d27167812f23159443a1e3ba8e76 ↗Source checked November 16, 2026
- Rusfertide for iron overload in haemochromatosis - Authors' reply. · retained source version 1:2025-06-05:current:64d7cba56a9debd9c6f9f5b6efe3dd35d35a36fb0a2b7b467fdaf227348d8cb5 ↗Source checked November 16, 2026
- Rusfertide for iron overload in haemochromatosis. · retained source version 1:2025-06-05:current:cc2a34cd5eb0b7b41c31e13be45e4389350dce11af4253d615ebbf3ca151a338 ↗Source checked November 16, 2026
- Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. · retained source version 1:2025-06-05:current:8b375ba88f541f877d70569b68c87e9a19561a42d5828577a4a9da956b787d8c ↗Source checked November 16, 2026
- Rusfertide for the treatment of polycythemia vera. · retained source version 1:2026-10-31:current:9cfe6fbaf2e1ddf16dce802b6db311ea7fe5404ec9b888f0ef2bedc88e3dd4c5 ↗Source checked November 16, 2026
- Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice. · retained source version 1:2021-04-23:current:529dbdb815882f6db60c131ec6b0de590c49356cad87a36dde73720572b9e04c ↗Source checked November 16, 2026
- Salmon calcitonin in the acute management of hypercalcemia. · retained source version 1:2019-08-28:current:e983550d3b158f124f72a10ad77d832b21ed07413e6c50e51e447f7cac73a36e ↗Source checked November 16, 2026
- Salmon calcitonin in the treatment of bone metastases. · retained source version 1:2016-11-23:current:74473af35e01fa737bfb138796f60f58834e3fc861918b78f9262dae977c50fa ↗Source checked November 16, 2026
- Salmon calcitonin in the treatment of elderly women with type 2 diabetes complicated with osteoporosis. · retained source version 1:2016-11-25:current:dfbba279d0273ecd3a50fa99059bf4dcd7eb9e7e1b69baebfd51230da8165f69 ↗Source checked November 16, 2026
- Salmon calcitonin in the treatment of postmenopausal osteoporosis. · retained source version 1:2019-06-19:current:5f00b1df3c6039cf3d156d8212565d1379dfb7fe10c9abab20f699e460433e30 ↗Source checked November 16, 2026
- Salmon calcitonin prescribing for acute phantom limb pain after amputation. · retained source version 1:2026-10-23:current:1690992bb1169a7d020add9da0a87f52f08dfa98dd9ad446aa5109f2106eebce ↗Source checked November 16, 2026
- Salmon calcitonin: a review of current and future therapeutic indications. · retained source version 1:2021-10-20:current:dc9b56ca29733010fe071ba2b59d56a5ef07fa3f5d172c4df4102eff153052b4 ↗Source checked November 16, 2026
- Secretin and body fluid homeostasis. · retained source version 1:2011-01-13:current:14b880fac4a3f94f5b231d4454db26a710012325540087c1a262c60b1053ce41 ↗Source checked November 16, 2026
- Secretin as a treatment for autism: a review of the evidence. · retained source version 1:2026-10-11:current:60852549cbb9efbe8858a3994bb44ab8499c97d47348469081adf18ceac892cf ↗Source checked November 16, 2026
- Secretin for refractory schizophrenia. · retained source version 1:2016-05-26:current:26cd0ed52d901d6d1e151fb6a5b4fe4f6d76dc3e1ce9fd6bc428f21d55d77e99 ↗Source checked November 16, 2026
- Secretin, 100 years later. · retained source version 1:2018-11-30:current:a3bc9573b7551822e82746bf2014deb504c267e5697d2300c9ab50d9d2764632 ↗Source checked November 16, 2026
- Secretin: a hormone for HCO3- homeostasis. · retained source version 1:2026-11-01:current:3def70ca33ecf04bfd0d89cef63fab7af954aab167efd43940e52ac2c1fe5ec7 ↗Source checked November 16, 2026
- Secretin: a pleiotrophic hormone. · retained source version 1:2006-08-04:current:483a3b97a556c9a10a8de23b541bb74df8a62e51fb9c06d7faa0892fbd3f30d3 ↗Source checked November 16, 2026
- Secretin: historical perspective and current status. · retained source version 1:2018-12-02:current:76efb0f7d04049dd7ac5595ee6af58efcdd61ac920f0a07069183933e5fcbfe2 ↗Source checked November 16, 2026
- Selank and its metabolites maintain homeostasis in the gastric mucosa. · retained source version 1:2019-08-13:current:3caef2596e947d7f78337c1432f1918b9d9d01c86e58df4e990d430579a6d19a ↗Source checked November 16, 2026
- Self-assembled Palmitic Acid-modified Thymopentin Functions as a Delivery System of Nanovaccine for Cancer Immunotherapy. · retained source version 1:2025-05-22:current:bceee22c8348fc721bfb2501f3003adf88a5b15122484fb0612a8674fadfcf0b ↗Source checked November 16, 2026
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. · retained source version 1:2022-02-01:current:d5f8ee6e316af95181837000f97a1a7561b9724dec5766f7efda10dffd1f695c ↗Source checked November 16, 2026
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? · retained source version 1:2021-10-20:current:daded1ed37f3a4740b3f8e1f6ea26cf01909ca7be57ee8ec8ae8953d210611d1 ↗Source checked November 16, 2026
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. · retained source version 1:2018-10-25:current:ce9838a7f8311731f957921bfe5963757aee3486dc6fbb1272aad56e35393d3c ↗Source checked November 16, 2026
- Severe hyperkalaemia with nafarelin. · retained source version 1:2019-06-11:current:ef0de86971528dc01a9649d9dad1a8e4330990ad380a284ab1b69b3752ed9bc8 ↗Source checked November 16, 2026
- Spasticity in multiple sclerosis and role of glatiramer acetate treatment. · retained source version 1:2018-11-13:current:b09a87f196d5c9f339a241f7b6d2cc54b42929dcd6ff681566966f01097c1e56 ↗Source checked November 16, 2026
- Spray congealed solid lipid microparticles as a sustained release delivery system for Gonadorelin [6-D-Phe]: Production, optimization and in vitro release behavior. · retained source version 1:2021-06-02:current:c4e9cc3496f4ebd91e39ead985cdbe25f71ed09d77b0eede285ad4b394e4eb8f ↗Source checked November 16, 2026
- Stability and purity profile of gonadorelin acetate: a high-purity gonadotropin-releasing hormone. · retained source version 1:2006-11-15:current:2e87abea7378194314319fa654a3750337616af61a9d866a7ef9417c0b4c9247 ↗Source checked November 16, 2026
- State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment. · retained source version 1:2019-12-17:current:924a8c8075c3a3c69fc8c66dc57e0ba43c10ae5579a11e7d866e5d2d9c7ec85d ↗Source checked November 16, 2026
- Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. · retained source version 1:2019-05-13:current:c5bd5afa69373c1a480036f18aace48d2f133affcfcf56d12124715cc4f2b175 ↗Source checked November 16, 2026
- Structural analysis of Salvia miltiorrhiza polysaccharide and its regulatory functions on T cells subsets in tumor-bearing mice combined with thymopentin. · retained source version 1:2024-08-24:current:cf584c7d52eefc3c0f0b430cf406d2a3cc2fa9613980c74c91717d3d9d97daca ↗Source checked November 16, 2026
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. · retained source version 1:2022-10-20:current:266ec2e956f602a3cf5441e73d0b374daf715a5931522f50dd222d825d7a8193 ↗Source checked November 16, 2026
- Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor. · retained source version 1:2023-03-14:current:7816465e168a63a7f42c0d34cc30f50553a64def31e14466517c43c97fdd2670 ↗Source checked November 16, 2026
- Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. · retained source version 1:2011-10-03:current:47ab98d3abc955e2b8e9a9f8bdad8cbe30b0068d0890a5b11c02c21e4812cd00 ↗Source checked November 16, 2026
- Structure-activity analysis of the growth hormone secretagogue GHRP-6 by alpha- and beta-amino gamma-lactam positional scanning. · retained source version 1:2017-11-16:current:288f4c59944d5f3a87c76028148446d91cdaf69f6d615088bb00178d1e67a17a ↗Source checked November 16, 2026
- Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis. · retained source version 1:2023-10-04:current:545249053197f145824070bbc1c797a48d7a5c0b3346792b8cda37c493d8e99c ↗Source checked November 16, 2026
- Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles. · retained source version 1:2026-01-27:current:109a8b02e5900a4986d9a0a9bcab75a42a64c4014034314e1d3a1675214627a5 ↗Source checked November 16, 2026
- Temporal, Phenotypic, and Treatment-Context Heterogeneity in Retinal Vasculitis Reporting with Pegcetacoplan: A United States Pharmacovigilance Study. · retained source version 1:2026-10-28:current:bbfcd0d4ea6e89b1aabe7abd63027920d2792e3cd12f3d05bb1c6cf9ba29873e ↗Source checked November 16, 2026
- Tetrahydro-β-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications. · retained source version 1:2020-04-08:current:f0c008c5f1dd497ad962484d5bb8330e27d30ecb43c3f90509e1654077e2321b ↗Source checked November 16, 2026
- TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. · retained source version 1:2022-04-08:current:ac526e7c36205a0be67504fef8e60e44404f25c3727d789eed7ae493df386845 ↗Source checked November 16, 2026
- The active monitoring of oxytocin research evidence (AMORE) platform. · retained source version 1:2026-01-27:current:7275701b421f4b71c71164c21dd699f9565f8a2a680ea7e4b57b56bbfdcd0e49 ↗Source checked November 16, 2026
- The current and future off-label uses of dalbavancin: a narrative review. · retained source version 1:2026-01-27:current:d95b5d82a92ff21a73f2d154abf6131278986cea1e9a21cf8c3356dbc9441b5a ↗Source checked November 16, 2026
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. · retained source version 1:2025-07-04:current:abbaa47a024e3ff12fee4ca52627a3f679852ccfd5a2f79f0af0567b8a2ab3ef ↗Source checked November 16, 2026
- The emerging role of the mitochondrial-derived peptide humanin in stress resistance. · retained source version 1:2022-03-11:current:f5f2ca7a3e7fd970c2d0d5e698f760110bb684e37edf0f9d2deffffde6ed3e0d ↗Source checked November 16, 2026
- The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men. · retained source version 1:2016-11-24:current:504bf07a0e0aa74553e250e49cc78a5a67bb4ed1a9ba40a0085d81572d1fa4d9 ↗Source checked November 16, 2026
- The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist. · retained source version 1:2021-10-21:current:936c6c6bc04d382a16b7e48752bd830dd6bb37e8d56bd22812d888b882b6694d ↗Source checked November 16, 2026
- The influence of Selank on the parameters of the hemostasis system, lipid profile, and blood sugar level in the course of experimental metabolic syndrome. · retained source version 1:2026-10-11:current:265bef19e94056f2a7d31a5930d833325e9b911b1dc600e931822f59132f9353 ↗Source checked November 16, 2026
- The Interaction between Amyloid Prefibrillar Oligomers of Salmon Calcitonin and a Lipid-Raft Model: Molecular Mechanisms Leading to Membrane Damage, Ca2+-Influx and Neurotoxicity. · retained source version 1:2020-09-22:current:7db8eca6150cd9d84019f6397cb63a7f0eec418225a4b2961b9cd336e60fd034 ↗Source checked November 16, 2026
- The International Reference Preparation of Gonadorelin for Bioassay: a comparison with different preparations of synthetic luteinizing hormone releasing hormone using physicochemical methods of analysis, different bioassays and immunoassay. · retained source version 1:2019-07-09:current:b42fb503fddb724d0147920982baf4ef5bbe21e44f36f07c887c692451532267 ↗Source checked November 16, 2026
- The lesion detection rate of Ga-68 DOTATATE PET/MR in multiple endocrine neoplasia type 1. · retained source version 1:2024-04-25:current:c0670cf437f339a0ce9d780ad386096b58a588d32f9e6d4b7ec395a0f9cfc812 ↗Source checked November 16, 2026
- The molecular mechanism of CFTR- and secretin-dependent renal bicarbonate excretion. · retained source version 1:2021-07-07:current:19df51ab6b90ba8fac6f259ca48a95d427dd098d264c8a2fcfb635bc7fb7051a ↗Source checked November 16, 2026
- The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration. · retained source version 1:2022-04-05:current:9cb75eed33f9359d48a0061d03262eddeceb9ec2e33c75cf7224389764a8a7b5 ↗Source checked November 16, 2026
- The orthosteric agonist-binding pocket in the prototypic class B G-protein-coupled secretin receptor. · retained source version 1:2013-01-29:current:2e3e422c3c6df4570aae0af8d95d48783eb7ec0cec37346b1cee6b971370a419 ↗Source checked November 16, 2026
- The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. · retained source version 1:2022-04-08:current:c178f72a73bc193a598632f3cde63a88e52559b2d21c1634a92211caf2609333 ↗Source checked November 16, 2026
- The physiological roles of secretin and its receptor. · retained source version 1:2021-10-21:current:ea28be71a6838618bbbf9c020ad27d197845626023f8ef9681380f6d01b70ec1 ↗Source checked November 16, 2026
- The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. · retained source version 1:2026-06-07:current:793a5a3dc7c432f08709fd2206cbdda9fbfdf9d8767d4a979f22a1c5f94fbfb0 ↗Source checked November 16, 2026
- The preliminary study of exosomes derived from thymosin beta 4-treated adipose-derived stem cells in fat grafting. · retained source version 1:2026-10-30:current:847fa458c6b89209fef6eeb98d4c1d1f7c8e8eb0e377c9d3fe297b1c281ef548 ↗Source checked November 16, 2026
- The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. · retained source version 1:2019-07-18:current:2a96832434b951a22a8a328d0088337e7d2ced0ffcaa25a8a7863790f76ab7e4 ↗Source checked November 16, 2026
- The role of dalbavancin in skin and soft tissue infections. · retained source version 1:2019-07-18:current:6fa2a70aed654227d58dd6afc432ba0fdc586c5028cae4dce0e4032d0897dc07 ↗Source checked November 16, 2026
- The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery. · retained source version 1:2018-09-26:current:109dac028a03eb0733eba98a299a9f82a2edbb6084ee337fafede2b154d66ba1 ↗Source checked November 16, 2026
- The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). · retained source version 1:2021-03-11:current:c53e64fd0f7eefc68509a389ee78bd3beaf9f0671dc20b8180fa6679c5adbe52 ↗Source checked November 16, 2026
- The role of functionalized magnetic iron oxide nanoparticles in the central nervous system injury and repair: new potentials for neuroprotection with Cerebrolysin therapy. · retained source version 1:2019-07-15:current:cfeda6d2714d1eac75c33d3a06be6685cbb4b9b8e44fca232c52b1eb50af8ee2 ↗Source checked November 16, 2026
- The role of humanin in natural stress tolerance: An underexplored therapeutic avenue. · retained source version 1:2022-01-11:current:45e6f113ee058da6971339fc848e6e6a31bf72233d6059eff0b7074c9b7b4906 ↗Source checked November 16, 2026
- The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. · retained source version 1:2024-09-21:current:795f5c0a3efa2636403880b6e725cd7437d93dcf2c4117d290af265502e0eeb7 ↗Source checked November 16, 2026
- The role of nesiritide in heart failure. · retained source version 1:2014-07-30:current:13061a6f61ac92b1dcbaed64319dae36c651e96a89a7614b6d025410db53ec89 ↗Source checked November 16, 2026
- The role of secretin in the cerebellum. · retained source version 1:2022-07-16:current:5b708271427e1c8f6e58e118897669d72731711960ec31703240c21c9f4c928c ↗Source checked November 16, 2026
- The use of interferon Beta and glatiramer acetate in multiple sclerosis. · retained source version 1:2015-11-19:current:6c24bfdfd5e7a7c73055554b6e6e29f064f853cadf7c1f5663c3a69084c2ec08 ↗Source checked November 16, 2026
- The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure. · retained source version 1:2019-11-09:current:5bb3ad41d1cc2a619ffbaf1c9c3e707ff266986195b38c63469af1204a36c5ac ↗Source checked November 16, 2026
- Thermosensitive Hydrogel Based on Poly(2-Ethyl-2-Oxazoline)-Poly(D,L-Lactide)-Poly(2-Ethyl-2-Oxazoline) for Sustained Salmon Calcitonin Delivery. · retained source version 1:2021-03-25:current:657ac76300fa2824dc9fd4620f0a1bcaeb71ab8b0f49ddc69f40965786c61cf7 ↗Source checked November 16, 2026
- Thymopentin (TP-5) in the treatment of rheumatoid arthritis. · retained source version 1:2019-08-28:current:120d4fb50111c6c3283b249223ac112bca8d4b0b5b6d65b668f041257449c362 ↗Source checked November 16, 2026
- Thymopentin and splenopentin as immunomodulators. Current status. · retained source version 1:2026-10-11:current:8df2eaaaea68208bfc6f45ef3e7c022c9977a901d13e274dae52e6be28b105a1 ↗Source checked November 16, 2026
- Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients. · retained source version 1:2026-10-20:current:9fe12a860c2f93570bf5df4d56b03a7c123fc0ac43592e03a1fc1820bda76b3d ↗Source checked November 16, 2026
- Thymopentin in dermatology. · retained source version 1:2019-10-29:current:855d2ff0cc791815c70f05c533b213fc33becd51e27363b900fcdda456dbd6b0 ↗Source checked November 16, 2026
- Thymopentin prophylactic treatment in patients with recurrent respiratory infections. · retained source version 1:2013-11-21:current:741692f1688e780e1742ad4c926b116377abf0693751eec3aefa9d60c7659f01 ↗Source checked November 16, 2026
- Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy. · retained source version 1:2026-10-11:current:793581bf65ffbd96ccb559367043a81c566db75e57aec6bcf05f02527a5a16cb ↗Source checked November 16, 2026
- Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations. · retained source version 1:2019-05-01:current:5ee6ef22321e60376fbe2f8df13245f4e458d329f0dba70e692bc138b0741604 ↗Source checked November 16, 2026
- Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study. · retained source version 1:2026-10-20:current:aa10dc14b179c318737f72f8469f7fa2d33bb57e0baf37ae4121ab3eea98adf6 ↗Source checked November 16, 2026
- Thymopentin treatment of rheumatoid arthritis. · retained source version 1:2013-11-21:current:ae782fe38529c607740d1630966745d25b9869c7472c026ba17a9f0e5b379419 ↗Source checked November 16, 2026
- Thymopentin treatment of selective IgA deficiency. · retained source version 1:2019-11-01:current:c9c56f9776a64e750d859a2eeb7be3ee357064501d48f7e7157248838c9e260f ↗Source checked November 16, 2026
- Thymopoietin to thymopentin: experimental studies. · retained source version 1:2019-11-01:current:bf9439418a7b783d6cb45b48a41ca95ebe7276592a57a7d054e7a600f95508f1 ↗Source checked November 16, 2026
- Thymosin beta 4 and the eye: the journey from bench to bedside. · retained source version 1:2026-01-27:current:e12a4ecb644226b1e77c901a110f5414bbbaeb575419691ee5976622a868629e ↗Source checked November 16, 2026
- Thymosin beta 4 and thymosin beta 10 expression in hepatocellular carcinoma. · retained source version 1:2026-01-28:current:8cb983311ebddd790dbb5ca08612e296b23c0b4985bb2ddab30d04f1aefa102f ↗Source checked November 16, 2026
- Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids. · retained source version 1:2026-06-16:current:6b01089f4e9f72f5cc8aa54d6c696b9703f8c51df907ecfc3c204d8fdc0910ea ↗Source checked November 16, 2026
- Thymosin beta 4 interactions. · retained source version 1:2026-01-28:current:3bd79600d91f64084291ea199356bb965916c61a1d9b2c0734aa5c2425d59b83 ↗Source checked November 16, 2026
- Thymosin beta 4 is dispensable for murine cardiac development and function. · retained source version 1:2026-01-28:current:16c900df59d1748d3027c5b3eb379585dcc0c780e3b200b06e32fb0884864ebb ↗Source checked November 16, 2026
- Thymosin Beta 4 Is Involved in the Development of Electroacupuncture Tolerance. · retained source version 1:2020-09-30:current:8b53210784d33b2297d52427364cf2d4f10681de801cf9eeff36a5f9bc8a1e7e ↗Source checked November 16, 2026
- Thymosin beta 4: An emerging therapeutic candidate for kidney diseases. · retained source version 1:2026-07-21:current:67da7e4d0db4df5230a6273f3b36cc9f165eb5c174a93e5383f61df57078ed4a ↗Source checked November 16, 2026
- Thymosin beta-4 and the eye: I can see clearly now the pain is gone. · retained source version 1:2026-01-28:current:1151d9a090c17862aa908394e27502563aae7c21264ae38cab108079745fb014 ↗Source checked November 16, 2026
- Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. · retained source version 1:2026-01-27:current:e9c748763366bc2cda5f8bb666609d36b707eb42d1335ae47b6b71530a2ee6ff ↗Source checked November 16, 2026
- Time-of-Flight PET/CT Imaging of Ga-68-Dotatate: Normal Pattern, SUV Quantification, and Differences from Non-Time-of-Flight Imaging. · retained source version 1:2024-06-28:current:5860e73a62ebed0fd5a96f5583c8417fce114518eb6e97b8f55a92577a19aca8 ↗Source checked November 16, 2026
- Tirzepatide in Adolescents With Obesity: Research Summary. · retained source version 1:2026-11-15:current:cc90af20c8646eeb5968abf14b2b52a110ca278ff20fa4878dfc37fbdb13ac72 ↗Source checked November 16, 2026
- Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. · retained source version 1:2019-08-30:current:15735a0dce25ba8d0172ce7ae6217c08432a65cb6c6dde8d743c0c110092af4c ↗Source checked November 16, 2026
- Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. · retained source version 1:2024-11-25:current:63505f6b294578739710d9cf36f9e7005f5d3283a49a9e3756d14dce80a07f87 ↗Source checked November 16, 2026
- Translational pathways of oxytocin therapy in schizophrenia: bridging negative symptom domains and neural mechanisms. · retained source version 1:2026-08-13:current:c3cee32ba9a527a190b31516332ffb07c7b7d495e192d6b44e9974f383201d3a ↗Source checked November 16, 2026
- Transplantation of Endothelial Progenitor Cells in Obese Diabetic Rats Following Myocardial Infarction: Role of Thymosin Beta-4. · retained source version 1:2026-01-27:current:b8205bbb22ca115529c8aee961ca3fa2be229896e32238f19480bf5c72e6cba0 ↗Source checked November 16, 2026
- Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate? · retained source version 1:2022-07-16:current:3e20ef3f4f343c2e4d9f2aefc84873863f019a8bb6962245d38553cc70718674 ↗Source checked November 16, 2026
- Treatment of geographic atrophy: an update on data related to pegcetacoplan. · retained source version 1:2025-07-30:current:fa7a20e661033fffddd6bb73c56edcc93782bc33b65d64394729a15808d4b6b3 ↗Source checked November 16, 2026
- Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. · retained source version 1:2026-01-27:current:7eb2122dd25951059fdf8ef438a2e3f9d201de868c1c07152018e1b331d4568e ↗Source checked November 16, 2026
- Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. · retained source version 1:2026-03-24:current:9fa19db13ff515bceed9c0ce6b531128642090c45badd573447b730a80714207 ↗Source checked November 16, 2026
- Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. · retained source version 1:2026-03-11:current:5a390de30118a14956317982be5bf5846d42d5fa435fa69902e07ae87f610da5 ↗Source checked November 16, 2026
- Tuning the double lipidation of salmon calcitonin to introduce a pore-like membrane translocation mechanism. · retained source version 1:2024-05-25:current:ff2862c1697a2b97c5408ceb7b3efe29855b75b741752e09b2099c4fccf1f41a ↗Source checked November 16, 2026
- Type II Turn of Receptor-bound Salmon Calcitonin Revealed by X-ray Crystallography. · retained source version 1:2021-02-05:current:3bbf188d2c016b213d07b93e129dc20787e2436698ab81487207ca57aa3ceb1b ↗Source checked November 16, 2026
- Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study. · retained source version 1:2020-03-04:current:d7b1709600b8c80c1d67d695fa8096086d4952d0cda5eb1e47d784271e6dc0d8 ↗Source checked November 16, 2026
- Unravelling the role of Humanin. · retained source version 1:2019-11-08:current:cf01783f05034f2414dda223ec215252dca32366978595637dd38be0b8dee40a ↗Source checked November 16, 2026
- Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. · retained source version 1:2026-11-09:current:9096c5c964d081bd18a6344ac479255bd3ae15f02d421509ac6104af90efd28b ↗Source checked November 16, 2026
- USAN Council. List No. 419. New names. Mecasermin. · retained source version 1:2007-11-15:current:6ba99c8c02fcafbcdaad14bb92e6178d68934c966ee578afc4f5dccac3810e06 ↗Source checked November 16, 2026
- USAN Council. List No.431. New names. Metreleptin. · retained source version 1:2017-11-16:current:4979554b23ee1bd39b28cc79804c87ec03d0db67c4500122ec687cf5b11c5e9d ↗Source checked November 16, 2026
- Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis. · retained source version 1:2026-10-12:current:063fcda0e2748010fa9a4c41166c13da6ac3be00ab934e687d80530a9e4e4278 ↗Source checked November 16, 2026
- Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. · retained source version 1:2019-07-07:current:e236b6c1cb8b99262cc0f2395fd69712707ca0849560934d81639f7edef5a7c7 ↗Source checked November 16, 2026
- Use of Selank to correct measures of integrative brain activity and biogenic amine levels in adult rats resulting from antenatal hypoxia. · retained source version 1:2026-10-11:current:e4ad67369fb9f41a808f4916024416cbf631e747b2967bb4c67fad347364f55d ↗Source checked November 16, 2026
- Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. · retained source version 1:2026-01-27:current:faafc56803e6e0dafefea5b1940e2db8b1f8ca28be0b0d312b12a4434429da6c ↗Source checked November 16, 2026
- VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy. · retained source version 1:2026-10-13:current:669295a84451d46a3631e2ef9c55cecfebed46ab2dc6f1ca83a466e02fbbbba5 ↗Source checked November 16, 2026
- Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. · retained source version 1:2026-08-12:current:2bfb38e8b3d404ff0f81915c74aedaa11a7167350cf30b41c6ecdf8ac7c1e482 ↗Source checked November 16, 2026
- W(h)ither metreleptin for lipodystrophy and the metabolic syndrome? · retained source version 1:2021-02-04:current:1d0c5810f37ea51232730bd8508dbffef20edf2c35fbe307ec82f356a0d2c5e8 ↗Source checked November 16, 2026
- Watch out for a revival of peginesatide in sports. · retained source version 1:2017-11-16:current:7f266d61ff3218b119b68cdab94ec6a0b8cd6299171ca8cdab2aa53b2d13930e ↗Source checked November 16, 2026
- WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy. · retained source version 1:2023-06-06:current:a5bd3b6edd913f632f249ce8bd096db791e0e43f3edce3a4ee959d4c2fd844b7 ↗Source checked November 16, 2026
- Zn2+-triggered self-assembly of Gonadorelin [6-D-Phe] to produce nanostructures and fibrils. · retained source version 1:2019-10-22:current:3917f94eb284654dc9d0d17a1ae7669bdd4b106bcdcbbea8d03da495aaf2702e ↗Source checked November 16, 2026
- Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series. · retained source version 1:2022-03-17:current:21a6d571e71eae1c622448a401f96a2443ad7a49f57ddafb38ed37cb94295a3d ↗Source checked November 16, 2026
- [A review: the role of antimicrobial peptide LL-37 in chronic sinusitis]. · retained source version 1:2022-12-07:current:c56a49bae02d4e633027b5649e45681c64e1a14a107d9d6986d79eb8b0097c2b ↗Source checked November 15, 2026
- [Activity of growth hormone-releasing peptide-2 in cultured cells of human pituitary adenoma and its interaction with growth hormone-releasing hormone and somatostatin]. · retained source version 1:2018-12-01:current:d071eaf18df9213adbc7a9f488fa15e18c93c27b1d8422c6aac373af4abe6197 ↗Source checked November 15, 2026
- [Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B]. · retained source version 1:2013-11-21:current:ce4bedf677d2e3dec0622e382e90416c4152770e373e24683113569398dd910f ↗Source checked November 15, 2026
- [Decapeptyl (triptorelin) in the treatment of endometriosis genitalis externa]. · retained source version 1:2018-11-30:current:eec64a6691df7519fc52573e7c288340a74bbe99a298acf0a347609c48c3c42e ↗Source checked November 15, 2026
- [EXPERIENCE WITH THE USE OF EPTIFIBATIDE IN ACUTE CORONARY SYNDROME DURING CORONARY INTERVENTION IN PATIENTS OLDER AGE GROUP]. · retained source version 1:2018-12-02:current:5b738af0a6717e3087773a3fa7e393b36c53399cef5030f1b64bd561b70b2681 ↗Source checked November 15, 2026
- [Hysteroresection of submucous myomas after treatment with zoladex]. · retained source version 1:2013-11-21:current:4e2e71affae07d38631a47f664e84f14d4323040ea65083361b44a3d1cdb535d ↗Source checked November 15, 2026
- [Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix]. · retained source version 1:2013-05-29:current:c6bd128f891a448d8a150e67fdb5a1872fe71b75df0368e76fb4d6252105798c ↗Source checked November 15, 2026
- [Meta-analysis of terlipressin in treatment of hepatorenal syndrome: an update]. · retained source version 1:2018-12-01:current:9acec7ee6b48928d3fbc234827634d235dbd848c9aefaa29d78495ec17f1290f ↗Source checked November 15, 2026
- [Multicentre randomized trial comparing triptorelin medical castration versus surgical castration in the treatment of locally advanced or metastatic prostate cancer]. · retained source version 1:2019-11-10:current:25ba3d0df38450ad0bf1e8906816a3798e5e54798f9e7037406a80d3f5ca5278 ↗Source checked November 15, 2026
- [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]. · retained source version 1:2019-12-10:current:d0678ed82ae39f8f70242810ef945350431ed7d99cd4a175e48afde3f1376dc1 ↗Source checked November 15, 2026
- [Pharmacodynamics of triptorelin]. · retained source version 1:2018-12-01:current:101ef19489bcb4d91e43953e8b3879d5159faf7cab250022760bb68b8f366b7d ↗Source checked November 15, 2026
- [Pharmacokinetics and pharmacodynamics of triptorelin]. · retained source version 1:2019-11-09:current:2d7bf363b4825254796992d7a87b9a52962c84569ae12520b8adf2c16baf0a7f ↗Source checked November 15, 2026
- [Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer]. · retained source version 1:2025-05-27:current:f8483e63d7d5b296b010c820396f61b5eed40e02791290494215faa13ec6f92c ↗Source checked November 15, 2026
- [Progress of researches on the antiparasitic activity of antimicrobial peptide LL-37]. · retained source version 1:2024-04-30:current:12bfb0c433040599028107bbd6ff7f5ac05645ecde6d03ef52f818592da200e2 ↗Source checked November 15, 2026
- [Prophylactic use of icatibant before tracheal intubation of a patient with hereditary angioedema type III. (A literature review of perioperative management of patients with hereditary angioedema type III)]. · retained source version 1:2016-12-30:current:928eb71ec5e76875a3cbcac1c42a6fe487eedc2571f0f61ef35c8a7895ee4f40 ↗Source checked November 15, 2026
- [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications]. · retained source version 1:2026-08-13:current:26d6c494cf381bf10fce8c35350ee0175046dcba360d236609496007c27b0da0 ↗Source checked November 15, 2026
- [Revisiting the vasopressin V2 receptor]. · retained source version 1:2025-01-09:current:b01bdc35a9f07e7e2ec6dd34ed9731bb56dff8c4008c8a62078debc6c2568840 ↗Source checked November 15, 2026
- [Treatment of advanced hormone-sensitive prostate cancer using degarelix]. · retained source version 1:2026-10-10:current:14af73972c5315659d7c955dd62cd4772720eee862f122d9042d7fbb2ad6a88f ↗Source checked November 15, 2026
- [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment]. · retained source version 1:2018-12-01:current:38eb90712ec5d3371091f1c7f907e353ba8005639b4b7841b12ccc9377bf9979 ↗Source checked November 15, 2026
- [Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis]. · retained source version 1:2018-12-01:current:830b7ea73488759109790a60027858a4f967e371ebb365ee07b071325b4bf919 ↗Source checked November 15, 2026
- [Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature]. · retained source version 1:2013-05-29:current:ab59338618ef701cb71d6c014491ad28722c5b512a23906f3a6413577f89a092 ↗Source checked November 15, 2026
- [Using GnRH-agonists (Zoladex) in the treatment of genital endometriosis]. · retained source version 1:2013-11-21:current:7506e0870b854ac1c93c1c60bff29c0b68a1c427fe0ce5e79f6f36e998701994 ↗Source checked November 15, 2026
- [Value of eptifibatide during salvage angioplasty with coronary stenting after failure of thrombolysis. Report of a series of 41 patients]. · retained source version 1:2018-11-30:current:109c5823e46fb8bcc406d1548f1d6bc368158ae7758580ce52d29e3cc63684e5 ↗Source checked November 15, 2026
- 5-Hydroxypyrroloindoline Affords Tryptathionine and 2,2'-bis-Indole Peptide Staples: Application to Melanotan-II. · retained source version 1:2024-04-08:current:64b0ef94d28ffd0dfaf5c4febf35993ed2729d22dcbfbc0d68da789cb3b7c156 ↗Source checked November 15, 2026
- A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. · retained source version 1:2022-07-16:current:d824de79b3dcbdfdd726c598015ed019de7ece6d83663dac47cd75d55cb116ba ↗Source checked November 15, 2026
- A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. · retained source version 1:2019-10-23:current:7297c92a878ef77f6081c0bb8a2e5266b13c96530863bec690946f53f9a3f1ff ↗Source checked November 15, 2026
- A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. · retained source version 1:2026-01-28:current:8c5cab4b2691a5c47ec21e60b95cbc68e41a9642c930939625b7a163186d5758 ↗Source checked November 15, 2026
- A kisspeptin-10 analog with greater in vivo bioactivity than kisspeptin-10. · retained source version 1:2025-05-29:current:29b72def48bf59786853c613908d85779d993618de8476d933291c063b85b6b4 ↗Source checked November 15, 2026
- A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke. · retained source version 1:2026-01-28:current:02b314668d693871212d2a56630eab597668eed9637231a8e75f2d6550bc2a57 ↗Source checked November 15, 2026
- A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study. · retained source version 1:2026-01-28:current:c68622c3f5d08319d554c01a5fa7dc35392b2e2522bd2e81752b2e8b59855b85 ↗Source checked November 15, 2026
- A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1. · retained source version 1:2018-12-01:current:dd9c0bfa8ed11d16fd5d8389973401c7bd2a046c069b364cf108d964bfbcabfb ↗Source checked November 15, 2026
- A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage. · retained source version 1:2026-11-09:current:b02b4b927f488f297ec04bdfd597025cb8f9d79174a1a06e58029b3d3fb01842 ↗Source checked November 15, 2026
- A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2026-05-18:current:41b285eaf9e6f9c324df31b5d27169b0109ce5f09daad2a6f90bf99d86c9bf47 ↗Source checked November 15, 2026
- A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer. · retained source version 1:2026-01-28:current:a60aa17e650fef00e19986fb270a33164e589d667ec8d02b4ec1905a19751257 ↗Source checked November 15, 2026
- A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma. · retained source version 1:2026-10-19:current:9da073f50d79e3be28b2c62d3a7ace37f86dcda5442a80e231ac5efc528cb96d ↗Source checked November 15, 2026
- A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. · retained source version 1:2021-11-22:current:4f2338798225b412464c6840977c321bd9720d8df6dae0432e6bef9b85b402e6 ↗Source checked November 15, 2026
- A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. · retained source version 1:2017-11-07:current:ec7c8bc0749b153600ec6b8b788599df0b8cafd3f344daca2379daa9d3267af0 ↗Source checked November 15, 2026
- A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. · retained source version 1:2024-06-10:current:5a88dc3047e488057c178036bbefe5873ec4f2454c994e040ac64989489ee770 ↗Source checked November 15, 2026
- A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy. · retained source version 1:2013-11-21:current:59b0ddaca5661e06d62e07be94033f75960e22e56c7d23d19730eab6f7d1452a ↗Source checked November 15, 2026
- A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial). · retained source version 1:2023-11-10:current:5b253f19f4aae3028c3b8a283393ce5ff99972110ba45167a84ba04a4369b4fc ↗Source checked November 15, 2026
- A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. · retained source version 1:2024-08-21:current:8b7aac649f7afc0fb3c61fd844497006c668948dabc6f1b11993f094ad2fdcb7 ↗Source checked November 15, 2026
- A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. · retained source version 1:2018-12-01:current:478b5afff99951af12d03b2f01f31c6b9f89c0d45ff23328cbe1110a8fb2824f ↗Source checked November 15, 2026
- A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. · retained source version 1:2026-01-27:current:0d788aef6d46faa61a60fce459900a31b131b9ed5c9c490220e935d0fe96022d ↗Source checked November 15, 2026
- A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. · retained source version 1:2019-08-16:current:2200be946737b22faca30d7dc92b488543ddff4ecc7449158c39c1e2c6c8fcae ↗Source checked November 15, 2026
- A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis. · retained source version 1:2026-08-17:current:f383f0b3d6395b7092fe350a8f4383ce5e35d8e5276df3c1e4d1cc801587d30d ↗Source checked November 15, 2026
- A Real-Time NMR Method for Measurement of In Vitro Aggregation Kinetics Of Degarelix Drug Products. · retained source version 1:2021-03-24:current:bee13d21ce2949840ad27b43b7bc1a3d3f926ff4f0fa95bc21966f6e465d6d23 ↗Source checked November 15, 2026
- A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support. · retained source version 1:2021-12-14:current:9ea2a797597301d47123f8b6b320727cb56f76a4730506d589b1bbb97ad4df0b ↗Source checked November 15, 2026
- A review of clinical trials with eptifibatide in cardiology. · retained source version 1:2018-12-01:current:3013d684b8cd87be9075da5ebe40d1383d871c4059ec36bc0dd192998bfcb399 ↗Source checked November 15, 2026
- A Scoping Review on Salivary Oxytocin and Vasopressin Measurement in the Dog. · retained source version 1:2026-09-25:current:fefac0c14dccd19b824eaabea31ff886c0d07c1d296407758fa55c5ea3834733 ↗Source checked November 15, 2026
- Accelerated Colorectal Polyposis in an Immunosuppressed Patient With a Small Bowel Transplant Treated With Teduglutide: Case Report and Review of Literature. · retained source version 1:2020-05-29:current:1003cee386243440fb1cf4a4c9cecc6eb2250373ecaa75d54d2bf815e34bd6f1 ↗Source checked November 15, 2026
- Acquired transient vasopressin deficiency by cannabinoids and other substances. · retained source version 1:2026-07-07:current:3b7864ca25acc711632255341a355d3fe379053df2e0d5818d5589fa4039016c ↗Source checked November 15, 2026
- Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide. · retained source version 1:2024-03-07:current:3fcfcac80215f54ee16753ad4e3e89b86e8b89b0adf6032dd907f838da25fae3 ↗Source checked November 15, 2026
- Acute intraprocedural thrombosis during an arterial ductal stenting successfully managed by eptifibatide. · retained source version 1:2022-05-09:current:c623d7bbb874351edfec5e4d5bb7f8fb5564b8e001d2a6734876cf540c97c6df ↗Source checked November 15, 2026
- Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. · retained source version 1:2021-12-21:current:825583d99edbf57266bf44cb22fbef4414d1ea394aca98b0556d9fe108d231a9 ↗Source checked November 15, 2026
- Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. · retained source version 1:2022-03-31:current:5fa1522489975656d7b41ab76415651d25e0adfc786760db626de58cfa0b2a56 ↗Source checked November 15, 2026
- Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. · retained source version 1:2019-11-06:current:b910327fe733ef338b04171b16f1bfeabf377e93428a550828cf75edbe385a11 ↗Source checked November 15, 2026
- Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis. · retained source version 1:2021-06-17:current:e69dbd72447f88f48dfec108a5ae3112037e362712506d6832a4d660c9cfeb6b ↗Source checked November 15, 2026
- Adolescent Gender Dysphoria in Italy: Reflections on Triptorelin, Consent, and Care. · retained source version 1:2025-05-14:current:5094f17084d58a6681c629412867876fb4ee0b58e8e5e3f8bc8694d1cf4141eb ↗Source checked November 15, 2026
- Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface. · retained source version 1:2019-11-08:current:b8bb197989ec1a34c79d32b10809cf1d9920b937f6b5fc21ac907ba505182a40 ↗Source checked November 15, 2026
- Aging and Thymosin Alpha-1. · retained source version 1:2025-12-14:current:4306cfc99eb51a5989e82d127a8ba6a3047b5c75426373f7713a1c47411a6cac ↗Source checked November 15, 2026
- An efficient synthesis of deuterium-labeled degarelix acetate, a third-generation gonadotropin-releasing hormone receptor antagonist. · retained source version 1:2019-09-11:current:33dbc001e26613f129d2b43e4a09538655d234d624c5b35f143e754dc50968cd ↗Source checked November 15, 2026
- An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. · retained source version 1:2021-04-27:current:7cc036b8f0cdd888f1146ae4c86b7b856c11de08b4de30444067fbc12ec6e1e7 ↗Source checked November 15, 2026
- An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. · retained source version 1:2024-08-08:current:403f91c18021531331023bae40421c65028b041fad6dcf39b62152da94b66310 ↗Source checked November 15, 2026
- Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. · retained source version 1:2022-03-09:current:757f3d55dc9d72bb45cdd1e1bf1b111596b534e5dd6abaf64850537615524be2 ↗Source checked November 15, 2026
- Analytical Methods for Daptomycin Determination: Applications in Biological Matrices and Pharmaceutical Formulations. · retained source version 1:2025-12-01:current:028ab37fdd7c0bfc66302cb792c3d8accf7787851c779c52cd477516da534772 ↗Source checked November 15, 2026
- Angioedema by MDMA mediated by bradykinin. Role of icatibant acetate. · retained source version 1:2021-05-14:current:831803c2705cf2456ab8a1507eae846a5a8850b4dd3f03cbe26836b638b66a9b ↗Source checked November 15, 2026
- Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells. · retained source version 1:2020-03-09:current:35ff5e2bd39efe4e242f0d2ab767fc21b605a1d6de5687e42d66b322f9c0782d ↗Source checked November 15, 2026
- Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. · retained source version 1:2018-12-01:current:351da762af819f7a17c82093950d0b8886ac6622c86460ac80f4e0871557cbc1 ↗Source checked November 15, 2026
- Antibacterial function of the human cathelicidin-18 peptide (LL-37) between theory and practice. · retained source version 1:2022-12-07:current:32e2c715cd5b8ad6738574b6efda6ae9ce1b3fb9500699fae8058736aeed4f26 ↗Source checked November 15, 2026
- Antibiofilm properties of cathelicidin LL-37: an in-depth review. · retained source version 1:2026-10-30:current:d4fe8cd8a98b91e036841b62445b286d7aa3f85832c477865a6b668e1194235b ↗Source checked November 15, 2026
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions. · retained source version 1:2026-10-31:current:db82591e4f148ba537b3daa5cece1fb1d1f0310c4190d0cac05c49c8a32dc872 ↗Source checked November 15, 2026
- Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications. · retained source version 1:2025-08-31:current:d205fb9bcc89f85d72f3d06628d865de520834ce55da061800626829984aa3ce ↗Source checked November 15, 2026
- AOD-9604 does not influence the WADA hGH isoform immunoassay. · retained source version 1:2016-05-11:current:b2e33e990a6e2a97c1dddcc0b8ad0ae8887d4ca445fc4e46c081441a903c6ba2 ↗Source checked November 15, 2026
- AOD-9604 Metabolic. · retained source version 1:2007-11-15:current:1be23058dbfbf4ed51b953e757e89ca4328a43f372cc0b2573d86c8ad94c5bc8 ↗Source checked November 15, 2026
- Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU. · retained source version 1:2025-02-07:current:3d53234f935930a7a7a5c0614ff311abec077a8b63b94400cab362cebf21af3d ↗Source checked November 15, 2026
- Aptamers and MIPs as alternative molecular recognition elements for vasopressin and oxytocin sensing: A review. · retained source version 1:2025-05-10:current:0287d570a4f31a9d65f046b6ebf4b6956a6407ef5f90b00711ff2c17303a5174 ↗Source checked November 15, 2026
- Arginine Vasopressin (AVP) Deficiency: Diagnosis and Treatment - An Update. · retained source version 1:2026-01-09:current:79e6436395fa65e1f28513e3676a9dea8af970f5e6af76282c224ab96d7fc379 ↗Source checked November 15, 2026
- Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine. · retained source version 1:2025-04-02:current:e1711a637f2a238a57de61835df703e37063a22c07e7beebaeb9f63caa0081c3 ↗Source checked November 15, 2026
- Arginine vasopressin deficiency after surgical ligation of an unruptured anterior communicating artery aneurysm - a case report and literature review. · retained source version 1:2025-12-31:current:45efc261fd2b145ba48c77cf2cb4b28557d7f46e98e51c727f541c5e41bf8507 ↗Source checked November 15, 2026
- Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic. · retained source version 1:2026-08-13:current:9792ac575f54f4b1ad8dc697f835789192a2a94b200f7accb1102917848f668e ↗Source checked November 15, 2026
- Arginine vasopressin deficiency onset after COVID-19 vaccination with positive anti-rabphilin-3A antibodies: a case report and literature review. · retained source version 1:2024-09-13:current:1645a7f02fd9d459e97d22693eb4eb6c4c86c7109101da5abea0bdf79dd3fa5c ↗Source checked November 15, 2026
- Arginine vasopressin deficiency: towards a better characterization. · retained source version 1:2026-09-18:current:1414bf0621209d82eb251cca4151ed343cfa910e7e27bc33055579e2a1c366fb ↗Source checked November 15, 2026
- Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials. · retained source version 1:2025-05-22:current:cc8b040fbeccad842cc682fce778d73eeaf82176deb3eb5898dc1132ac7c4ca8 ↗Source checked November 15, 2026
- Assessing the performance of new chromatographic technologies for the separation of peptide epimeric impurities: the case of Icatibant. · retained source version 1:2026-01-27:current:f5d2672805a1460c79b737f4a827059921b456fd8ecd9bec85522be1732821af ↗Source checked November 15, 2026
- Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. · retained source version 1:2018-12-01:current:b543a827aae7ddd2e17c85fd98c42876e1bbaaabd0233295d665f2579c5e647e ↗Source checked November 15, 2026
- Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry. · retained source version 1:2014-11-20:current:60046ecb5b0c39f7d90987d6688ef4f7dad5230b3ba0b54898adcd7370d95607 ↗Source checked November 15, 2026
- Bacterial cell membranes and their role in daptomycin resistance: A review. · retained source version 1:2023-02-17:current:fd955988580048cd9ee8b38844fd2a5768df80c2561614a8de6a0f8dfe51c0b4 ↗Source checked November 15, 2026
- Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. · retained source version 1:2025-01-30:current:88326e6f259129de1c038f1c6cf6f3498c247d7f0008f13a8801d56adc7518ae ↗Source checked November 15, 2026
- Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acids. · retained source version 1:2026-03-07:current:b37e392ae70b49356012914ce127bd0fd46a6f392deab32c4eba15f0884264c8 ↗Source checked November 15, 2026
- Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery. · retained source version 1:2026-05-07:current:6ef7833e623dd4f4ba133876eb942166a162382cc713564f31bcaa1ad07c63d1 ↗Source checked November 15, 2026
- Bivalirudin as an Alternative to Heparin in Pediatric Cardiac Procedures: Evidence, Challenges, and Future Directions. · retained source version 1:2026-08-16:current:dec21f98daf8fb68b267ad92cba00420209e8e869e159cff49856677d29f6c69 ↗Source checked November 15, 2026
- Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. · retained source version 1:2026-11-09:current:116b3b720c050be5aeddd67d0192d5cd531b8b93524edc932a467a66291d28d7 ↗Source checked November 15, 2026
- Bivalirudin in Extracorporeal Membrane Oxygenation. · retained source version 1:2026-11-09:current:d8b8bbd7bdf63cd1c54a8efcd0144447eff6f8088b83658860a87782f00d1e18 ↗Source checked November 15, 2026
- Bivalirudin in pediatric extracorporeal membrane oxygenation. · retained source version 1:2022-06-07:current:a98dc927c4f0cd76f5123e424fcea4b0713503c4cd16ac6815bbe8ff03cbb74a ↗Source checked November 15, 2026
- Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis. · retained source version 1:2026-11-08:current:782762ec4d0db579d0ad4b7e15518feaf2da76a8ed5edd11e1904f9ba59d031c ↗Source checked November 15, 2026
- Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation. · retained source version 1:2026-11-09:current:c0836fd32be0e1013334b14d5892b7cb0a177620fa22ccb7c427280dc270ddfd ↗Source checked November 15, 2026
- Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. · retained source version 1:2021-03-18:current:7a7bc90983639b30e5797c61c19f9f7e6450af923847c1bec3dfa491edfc565a ↗Source checked November 15, 2026
- Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. · retained source version 1:2023-11-07:current:5d4829fbf6ffa906ad8ec16b767b528d2b35eb929f7ca4632cc3d56a9cf18230 ↗Source checked November 15, 2026
- Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis. · retained source version 1:2026-11-09:current:b532a4422ad3c7ae5f1eec365f5ba3c8b6a29472d29ac1d9e0b443f5a334f12e ↗Source checked November 15, 2026
- Bivalirudin versus heparin in patients with or without bail-out GPI use: a pre-specified subgroup analysis from the BRIGHT-4 trial. · retained source version 1:2024-12-03:current:040cabd6072a07734e3fb8f9ccb78b287134c5202da5eb5e7d52bab750b4e732 ↗Source checked November 15, 2026
- Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis. · retained source version 1:2026-11-09:current:a3627cb5905381d687d03e34253d59aa50ab453a544111a7a179e5379b6fc5f9 ↗Source checked November 15, 2026
- Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial. · retained source version 1:2020-11-09:current:f1be5a81a3c0c0545342d549162a97be793529c54a8dbce1c985bb982fa39363 ↗Source checked November 15, 2026
- Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis. · retained source version 1:2026-11-09:current:9034e783286e98e07dd09211b106fb70f0a6927e103c823ee27626948aebec69 ↗Source checked November 15, 2026
- BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis. · retained source version 1:2025-11-24:current:7e96362ba6b2eb07841998c86c2107e9fc321d7441e0fca1ac1786686c38cd5f ↗Source checked November 15, 2026
- Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). · retained source version 1:2018-11-13:current:6d420b688069797fbcd7c154d3b05c7207b71442cc2cb3e15549b96432c4ea7c ↗Source checked November 15, 2026
- Bone penetration of daptomycin in diabetic patients with bacterial foot infections. · retained source version 1:2019-10-24:current:f6341e470f5172579d6a4704a9ad741586392cb4ed3dd95dee734e566b795c7e ↗Source checked November 15, 2026
- Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures. · retained source version 1:2022-08-05:current:5a5790900ba05e608e9667475373517f1de199983cca14a0286209ae228244c2 ↗Source checked November 15, 2026
- Cathelicidin LL-37 in periodontitis: current research advances and future prospects - A review. · retained source version 1:2025-05-07:current:0259b10fccc2a74878c65713d80a4f7db3c988e3d9072739bd7ac3f50f62c55c ↗Source checked November 15, 2026
- Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus. · retained source version 1:2020-09-28:current:72131aba56ed62a23633a44bc35c8136b54ccc6a8062dfa17ffeec57f9ddccaf ↗Source checked November 15, 2026
- Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease. · retained source version 1:2025-01-17:current:c9b4084c72d2176c8d8bddd4a4e3d51e3b5004a1e772c341f8df1145a36641b7 ↗Source checked November 15, 2026
- Cetrorelix in reproductive medicine. · retained source version 1:2024-09-18:current:e39775b63994b2ad47239c7661e536f672834f92c5db3d0153c1c5aa53d1b7cf ↗Source checked November 15, 2026
- Cetrorelix in the treatment of female infertility and endometriosis. · retained source version 1:2019-09-17:current:9474faf123c19667e6c7b262ad8008d0d7ab48b7774cb857c4e9415f30d5a40c ↗Source checked November 15, 2026
- Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States. · retained source version 1:2026-08-28:current:b6c0596b44034a5adf82bc0fcfda58b5fc82f8ae6fdba6cf121cf5253fccca21 ↗Source checked November 15, 2026
- Characteristics of growth hormone secretion responsiveness to growth hormone-releasing peptide-2 (GHRP-2 or KP102) in calves. · retained source version 1:2019-09-05:current:0ef27668c5f6d667d63f4b43755ccbda2ec80b1bf8a9df39292bf73f9b3c59ad ↗Source checked November 15, 2026
- Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. · retained source version 1:2021-12-20:current:f8aa51f593228f645a83ad5004f6efd61a756a3b5fa5896375c7db91be0c3e17 ↗Source checked November 15, 2026
- Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. · retained source version 1:2022-12-07:current:cdfee98a1f3bb7eff3f3113e65c1f9bd0605ac19bed88f3122dc9574753d2307 ↗Source checked November 15, 2026
- Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. · retained source version 1:2022-03-09:current:0ee3748b7eea8f30e29acd284518ff0013b9cd218e4ac375ce85a53673d91b20 ↗Source checked November 15, 2026
- Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review. · retained source version 1:2026-09-29:current:f5d603c32e01271e609945a4d8e4cd8b3521239cb60764f0fb7e0ce900183af5 ↗Source checked November 15, 2026
- Clinical Pharmacokinetics of Daptomycin. · retained source version 1:2026-10-10:current:2b468a03ebff4db61a873fbcc4a0cec49d243a9d15c9ae4e4049d4af4fade6cf ↗Source checked November 15, 2026
- Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. · retained source version 1:2022-07-16:current:3a0c19e61e25d886838b0441d9e10e3d9c6b4852662a8ac01c9a859a4b6eeb0e ↗Source checked November 15, 2026
- CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists. · retained source version 1:2026-03-07:current:725261757d1f5058f95696de5a796fcac7912bd2cffef0991b458401e83c3ffc ↗Source checked November 15, 2026
- CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). · retained source version 1:2013-11-21:current:30b0f94cdf8b77b8c8c6b10bde56fff1026d2a76f9b3f83cc02b505f2bd7be3b ↗Source checked November 15, 2026
- Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series. · retained source version 1:2021-08-16:current:f9da8571d93aa28be0a11e0ceb90df368465ad530792d58f278469435793b537 ↗Source checked November 15, 2026
- Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. · retained source version 1:2019-01-11:current:f8dc3b0f53473654ac4b4e0f3400f5017a81f345a42a720d5f5bb91e71a9847e ↗Source checked November 15, 2026
- Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. · retained source version 1:2021-05-18:current:9aeb2d6c9c4b60679345e07050095ebc990c401bdbbf08de21dad2796d4fafdf ↗Source checked November 15, 2026
- Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. · retained source version 1:2018-12-01:current:b9b14dc42eb441555b20b11c2ebce965e8fd6edfbf4488822c2604cb7313177b ↗Source checked November 15, 2026
- Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. · retained source version 1:2026-01-28:current:ee7e29fa834d3cdfa9f4ee3dd5e2854f538d3823cfb5cf018066be4145009276 ↗Source checked November 15, 2026
- Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. · retained source version 1:2018-12-01:current:e36da2b8e3fa4c36ee6530e7f758f690da3ade5c4468c5d684653014d3d3101a ↗Source checked November 15, 2026
- Combining MALDI mass spectrometry imaging and droplet-base surface sampling analysis for tissue distribution, metabolite profiling, and relative quantification of cyclic peptide melanotan II. · retained source version 1:2021-03-01:current:d8d9a4c61d160c6088f3ba5f73d140f0cec69279c2e243dec162f076422ce37e ↗Source checked November 15, 2026
- Comparison of 12-Hour with 72-Hour Terlipressin Therapy for Bleeding Esophageal Varices. · retained source version 1:2018-12-02:current:15a1f907ae4c497b578dcb09bd4a483bb96263f993e7e3d3589ac5282ead1231 ↗Source checked November 15, 2026
- Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation. · retained source version 1:2023-04-18:current:a1a683723721c00f905c941cf3fe5f249d022c7ab40f2eb0c3eac00a0df4e6de ↗Source checked November 15, 2026
- Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats. · retained source version 1:2026-09-24:current:d20cdab6aac4c8df170ef6bc966c2fb82be725e8626db342dfcf7628c9a89c26 ↗Source checked November 15, 2026
- Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. · retained source version 1:2026-11-09:current:97f2e6f6a54057af8dfe967a28a701d17cfcb659ecac97b032fbbf18fab83b9a ↗Source checked November 15, 2026
- Comparison of ecchymosis rates with measurement of automated and manual blood pressures in patients receiving eptifibatide therapy. · retained source version 1:2018-12-02:current:d541a31b93e0f35edeb01f7ca45f1730f2b50c9784ad53574d1029d88c6e79aa ↗Source checked November 15, 2026
- Comparison of pituitary-adrenal responsiveness between insulin tolerance test and growth hormone-releasing peptide-2 test: a pilot study. · retained source version 1:2022-03-21:current:f5f5ad96d1d477b61e056cb96cd064d3015ebd46fa06928dce75e88b84ec18d3 ↗Source checked November 15, 2026
- Comprehensive nutritional assessment in short bowel syndrome with chronic renal failure on teduglutide therapy: A case report. · retained source version 1:2021-06-23:current:49c0b516625fc55e0e53a5962698ce6a4b7c0fa9ed37a3d5eb6a6e643f78a223 ↗Source checked November 15, 2026
- Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. · retained source version 1:2021-10-04:current:331647d15d8965f147dce58aa102ac80b227b7f281bff83e4e001777d61f0aa4 ↗Source checked November 15, 2026
- Copeptin as a Marker for Vasopressin Dysregulation and Diagnosis. · retained source version 1:2026-01-06:current:bac5b1484bde24e2ce7e8ee6262c11545e7d6d6b8517810352e2f4182273c812 ↗Source checked November 15, 2026
- Daptomycin and ceftaroline combination for the treatment of persistent methicillin-resistant Staphylococcus aureus bloodstream infections: a case series and literature review. · retained source version 1:2024-12-30:current:243fe11fcc8f0c15884849ea29665b8684442548071ed7bc8fc1f3115126c16a ↗Source checked November 15, 2026
- Daptomycin as an option for lock therapy: a systematic literature review. · retained source version 1:2024-03-22:current:b1d21e2c45b6428cd3d800609bbabb1fdb27e8c66fcbd3305dd30bbc9d56451f ↗Source checked November 15, 2026
- Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series. · retained source version 1:2025-07-11:current:b68891113230bbda81b3dd3371ed7ed87ecaaab9443f3cebef8a85b908161af2 ↗Source checked November 15, 2026
- Daptomycin for enterococcal bloodstream infections and endocarditis: reconciling clinical evidence, susceptibility testing, and regulatory frameworks. · retained source version 1:2026-10-13:current:67e4429ba37e18c694ede362e8722bb5ea95b352086201573c9b1eac930fe47c ↗Source checked November 15, 2026
- Daptomycin for the treatment of acute bacterial meningitis: A narrative review. · retained source version 1:2023-05-05:current:2d3922ef7b3692e2bcf7a1b9c00324fd3b6b04d603962ea1ca5d5e9b21faeec1 ↗Source checked November 15, 2026
- Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. · retained source version 1:2026-11-09:current:205afecc44f3ea2cc9bafddb21e45abe5b54152c4e2e1fbefa78785f2962716c ↗Source checked November 15, 2026
- Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review. · retained source version 1:2023-02-08:current:08bee0820bf5b17fc29b90c8a12407a6ca81cb639e3dd937043bca17fe49f27e ↗Source checked November 15, 2026
- Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review. · retained source version 1:2022-09-02:current:4535fcd472b33b7f2f040d3bb6f0ab7e0810894ab45c500d116e021e9b9bab1c ↗Source checked November 15, 2026
- Daptomycin treatment for persistent bacteremia in a pediatric solid organ transplant recipient: Case report and literature review. · retained source version 1:2025-05-19:current:6d095465cc37223f6b877d000808136b3f3b7c9e8a81b6b48516793efe9e89e5 ↗Source checked November 15, 2026
- Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis. · retained source version 1:2021-08-30:current:357f1c9be2cca17e982c1fb10ad3583e9bc0e3d9e7901e32cce90b1ec8d422a9 ↗Source checked November 15, 2026
- DAPTOMYCIN, its membrane-active mechanism vs. that of other antimicrobial peptides. · retained source version 1:2021-01-06:current:33010fafa6c7a3d00988b0382303e9df43eb039718eb9c8380a466b7647e52a7 ↗Source checked November 15, 2026
- Decoding LL-37: Structure and antimicrobial mechanisms against microbial threats. · retained source version 1:2025-12-15:current:81ffc7562f62edd1d151ae454bf5b1f421128e926d0350c4aa5d6e4ee7e0c3d9 ↗Source checked November 15, 2026
- Defensins and LL-37: a review of function in the gingival epithelium. · retained source version 1:2024-05-15:current:c05a5d1c43eac40010f534749b0ae4d0e22d9096b220baaf49653808837fc077 ↗Source checked November 15, 2026
- Degarelix (firmagon) for prostate cancer. · retained source version 1:2013-11-21:current:9ba14c348817594200d71e532029469897af62c610731caeb2b488bd9f2a05c9 ↗Source checked November 15, 2026
- Degarelix acetate for the treatment of prostate cancer. · retained source version 1:2025-08-04:current:8bd32370b4b945b458937522e56818789a3c0cb3c278382a606aff8ee67ac039 ↗Source checked November 15, 2026
- Degarelix as a new antiangiogenic agent for metastatic colon cancer? · retained source version 1:2021-10-21:current:4d353e334aa568d579a4509a6a06a1928541665f9059806b63ef0ff2ed603b68 ↗Source checked November 15, 2026
- Degarelix for prostate cancer. · retained source version 1:2009-05-26:current:fc6992720754d7b1ad06216cda6ee333a29a352455e65a31b01556dcc242f95b ↗Source checked November 15, 2026
- Degarelix for treating advanced hormone-sensitive prostate cancer. · retained source version 1:2025-06-23:current:15b6f0395855faeb060496b7d3b5ad12053d8b433be4d58a3f412f5cbeff574a ↗Source checked November 15, 2026
- Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. · retained source version 1:2022-03-11:current:a7ae0cbb1597911380a1c9fac67ec8282051896fc2e25495b87ba6b232a49151 ↗Source checked November 15, 2026
- Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. · retained source version 1:2024-07-28:current:03b111893bbfdfb169b31af4fb6cedbf34152a667f091416b91168dcd9470058 ↗Source checked November 15, 2026
- Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis. · retained source version 1:2025-10-31:current:3932cbbc6deef0594557666de4e460945d20ba8f84d65faa389f5f95dd3b60cb ↗Source checked November 15, 2026
- Degarelix: an antagonist to GnRH--theoretical and treatment considerations in paraphilia. · retained source version 1:2015-11-19:current:3b67ceb3a9c8159f2ed03c8ac1b2fd92a460ba5b59147feeb09bb5aef035056a ↗Source checked November 15, 2026
- Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37. · retained source version 1:2022-12-07:current:ed19bf12d4686186594d94d9c5bb9a945758f0a48bd3149b0a4984cc4dec116b ↗Source checked November 15, 2026
- Design, synthesis and evaluation of trofinetide prodrug based on diketopiperazine strategy. · retained source version 1:2026-07-11:current:244df2acb68c91d9b81d5b2b8ca918a7e51c006a6a84b9da4b90d2f1d9743e76 ↗Source checked November 15, 2026
- Detection of GHRP-2 and GHRP-6 in urine samples from athletes. · retained source version 1:2016-11-25:current:88756a2953f2139bcc8b09dd7bc75ef9265762493d1aa987378d6e19ab573e7c ↗Source checked November 15, 2026
- Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. · retained source version 1:2019-12-10:current:2f20509d251c8cf224d29575b1d9deb6a0bda60c01984c945105297610594518 ↗Source checked November 15, 2026
- Determination of melanotan II in rabbit urine using solid-phase extraction sample preparation followed by reversed-phase high-performance liquid chromatography. · retained source version 1:2019-08-31:current:6632b4c968d53f6473cec015f5fa67e43dc1d75ed6b89616eda2093e513b9316 ↗Source checked November 15, 2026
- Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions. · retained source version 1:2019-12-10:current:688479dff33182d26757c29c2898973ace8c73a3960d0c4fbe21a447fa2a8418 ↗Source checked November 15, 2026
- Development of trofinetide for the treatment of Rett syndrome: from bench to bedside. · retained source version 1:2024-10-31:current:1cd0d41cdd0d0c511086c0a7d2c41b13ee59c2ee1fe622398a410205ec38dbec ↗Source checked November 15, 2026
- Diagnostic usefulness of the growth hormone-releasing peptide-2 test as a substitute for the insulin tolerance test in hypopituitarism. · retained source version 1:2019-09-07:current:25f38b04202d95c113234cda65f2ad948658c818b8df77571abb75cf8aa226e9 ↗Source checked November 15, 2026
- Difelikefalin Acetate. · retained source version 1:2021-12-21:current:5de422e8a3b9be711a749b06ea3b0dc1bf16a76955949b8afeda48e289412a53 ↗Source checked November 15, 2026
- Difelikefalin for Hemodialysis Patients with Pruritus in Japan. · retained source version 1:2025-12-05:current:e7133fc4a976247b1c0c97bf6f998d2585fa2a7af95cb10ff7fff85ac79ced22 ↗Source checked November 15, 2026
- Difelikefalin for the Treatment of Uremic Pruritus. · retained source version 1:2020-01-27:current:96e1bee0ceed1848bd7b25252a133bc05df6b6c8c3a0a8b28873dcc821a49eae ↗Source checked November 15, 2026
- Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2. · retained source version 1:2026-05-26:current:df4dd457417db0dc693aa6cc1d27cfd4e933b8119e3a5184c13a49ba48429e2e ↗Source checked November 15, 2026
- Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2023-09-29:current:517f7cd38f14bb0e05b4f4ed4b7b002180cb50cb468c095a29e6243478056790 ↗Source checked November 15, 2026
- Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2023-09-29:current:595b0123b8641c0a998479218845a319bb003ef36555e8a2476ad6f8dc164f84 ↗Source checked November 15, 2026
- Difelikefalin in Hemodialysis Patients with Pruritus. · retained source version 1:2023-09-29:current:f8f03417a01638983e66ff337ca6d0e664623c4bacc4a8387f8e6371c1d61272 ↗Source checked November 15, 2026
- Difelikefalin in Hemodialysis Patients with Pruritus. Reply. · retained source version 1:2020-05-25:current:8f92abb1fed57e180c9f25b26c1ea763903f1c293e2323c5d8ea4c43db46082b ↗Source checked November 15, 2026
- Difelikefalin in the treatment of hemodialysis patients with pruritus: a systematic review and meta-analysis. · retained source version 1:2025-01-04:current:455e9c852376153aca1b2e7b21efa24e4a2df0798d9a727c6104812d7588689c ↗Source checked November 15, 2026
- Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia. · retained source version 1:2026-10-15:current:72edcd9bc2903abde6e389498761c605c56630794a4534fe3cff9cce30bb3d85 ↗Source checked November 15, 2026
- Dramatic Regression of Parathyroid Gland Swelling After Conversion of Calcimimetic Medication From Cinacalcet to Etelcalcetide. · retained source version 1:2019-12-10:current:8c305765838e4f7ef32baf09795c6fac1b342e1f11044d717b08c308288a8e7e ↗Source checked November 15, 2026
- Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. · retained source version 1:2026-10-11:current:6468e78b57c004bcf950b332f5cc738720e6b42b14d379d01da825a46dba9250 ↗Source checked November 15, 2026
- Early cessation of triptorelin in in vitro fertilization: a double-blind, randomized study. · retained source version 1:2018-12-01:current:20c16786a32ba8897a9b92a228f4475956c766d971e4b030c3970ff6c9fc9512 ↗Source checked November 15, 2026
- Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. · retained source version 1:2026-05-01:current:8f05fae5c4055488879e12e8e4d72529dac9eef31521102b909f84a288647c10 ↗Source checked November 15, 2026
- Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials. · retained source version 1:2021-02-12:current:ee449ad3dbdbc12f708cf9392d4ddb7b48c848574ebb820eb09e931d27e70f04 ↗Source checked November 15, 2026
- Eptifibatide in coronary intervention: past time for the next chapter. · retained source version 1:2018-12-02:current:85e71b73355144f0713c955288755f34ad9f255a74d00a0ef8933e721756f620 ↗Source checked November 15, 2026
- Eptifibatide in post-infarction angina patients who refused intervention: Ajmer postmyocardial infarction angina eptifibatide research (AJMER) study: a pilot study. · retained source version 1:2026-01-28:current:dc9ab2b1b18e2a22b7e7a41539f4d009fcadf7f018bcf3891124031d8d06d55c ↗Source checked November 15, 2026
- Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion. · retained source version 1:2020-11-02:current:ee8ccd87765407b9c5bf9cfec62a6783f65d88c6cfe9d6668cdec8e026481d93 ↗Source checked November 15, 2026
- Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis. · retained source version 1:2024-09-05:current:d7ccf8df8a6285b695efc4cd134765524a20f5cd7fa7ca18182a9430398d02ad ↗Source checked November 15, 2026
- Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice. · retained source version 1:2023-03-31:current:80948f8cb27c44866cd7fc561a5b144ead5c78bddd81a7c9730c7306f6866b9e ↗Source checked November 15, 2026
- Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. · retained source version 1:2018-11-30:current:2197976502c4a30a77d46c312a3e4ce922e89e5011d3f8ec7b58b98d63d49a1a ↗Source checked November 15, 2026
- Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review. · retained source version 1:2023-10-10:current:cda527d3ead730db258919e236d7346a9f068850f63575cbd2f53d643a0020e4 ↗Source checked November 15, 2026
- Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy. · retained source version 1:2019-08-22:current:5e6a898eb42f885ed48a7034ef35e6454de24da13e9121ecc6e2e95391549386 ↗Source checked November 15, 2026
- Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism. · retained source version 1:2021-12-04:current:e3d7795bc8d4ec29296b8207454996bf01626e567a364ff25b7bf392b2fe82a8 ↗Source checked November 15, 2026
- Etelcalcetide (Parsabiv) for Secondary Hyperparathyroidism in Adults With Chronic Kidney Disease on Hemodialysis. · retained source version 1:2024-11-09:current:5d48c19b757a1d03d966d4da360933113c00dae94a85d8ff7fc6b9d737935925 ↗Source checked November 15, 2026
- Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation. · retained source version 1:2023-03-08:current:2e252319ad88731d01a4bb08d2e99e7825e8305efc9e03076967d1d2606e11f1 ↗Source checked November 15, 2026
- Etelcalcetide for the treatment of secondary hyperparathyroidism. · retained source version 1:2019-12-10:current:5c6e83aa1d93c34a9a820fe8905a227702325cb60d999b410b45a8e081327aa1 ↗Source checked November 15, 2026
- Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. · retained source version 1:2026-10-12:current:8d8bd4409602d7bd0f843997097f60669c0d177679304f21ce38e7587e46839b ↗Source checked November 15, 2026
- Etelcalcetide use During Maintenance Hemodialysis and Incidence of Parathyroidectomy After Kidney Transplantation. · retained source version 1:2026-05-18:current:66f8c490dee0d01821535f2f73ffa6a044750339e177d7e0f3024457c3e4bb06 ↗Source checked November 15, 2026
- Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up. · retained source version 1:2026-09-16:current:d7317de980c2831334b2b12f00799560b1c2b2e4d7eaba1a693ec4bbffd9e703 ↗Source checked November 15, 2026
- European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia. · retained source version 1:2013-11-21:current:cb5e4203fa0156c5a42f91276cc1ee475f6e9dffc19f0daeca0cf44bda1ef7fb ↗Source checked November 15, 2026
- Evaluation of Daptomycin Use in Outpatients With Methicillin-Sensitive Staphylococcus aureus Bloodstream Infections. · retained source version 1:2025-02-04:current:04fb875bb60e3e978a36d41908559433d9b89dc11e3261349f4722787d39e663 ↗Source checked November 15, 2026
- Evaluation of degarelix in the management of prostate cancer. · retained source version 1:2024-04-09:current:5a3bf71daf9aaefef898a6df23f418644d90dad1733f3dc8d6e70cfc5e438a0c ↗Source checked November 15, 2026
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. · retained source version 1:2019-07-01:current:9802ba03cabd3b4358de7d7ef2b98ae8cd4e64109b4620f7590a37b45dad85fb ↗Source checked November 15, 2026
- Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital. · retained source version 1:2026-10-10:current:a3ba357a17193d1832659e99ca63374616f42d30e7ff347adfc41c341e884241 ↗Source checked November 15, 2026
- Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. · retained source version 1:2022-03-11:current:32b11f3f3ea970e9952cb8854d353d52791472d9bbcb802096772e8f7eb9de07 ↗Source checked November 15, 2026
- Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression. · retained source version 1:2025-05-21:current:be49efa37caf76267dcc95fcbb630bf5147e3f61369474c111400087a7fbd037 ↗Source checked November 15, 2026
- Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice. · retained source version 1:2019-09-29:current:37ff8c082110cdeabdb7ae18a904ccf2c580b5487b956b89b5897d52bcf54f95 ↗Source checked November 15, 2026
- Exceptional treatment of COVID-19 pneumonia with icatibant. · retained source version 1:2025-09-30:current:2b3a9bbc0ab39aa8f9b68d3c46c80e91334100c2357161d5721edb6218621142 ↗Source checked November 15, 2026
- Experience With Teduglutide in Pediatric Short Bowel Syndrome: First Real-life Data. · retained source version 1:2021-05-20:current:70864f5b6645ced5b9b9df34d46176fc085246135733eb1487dca309febf16c6 ↗Source checked November 15, 2026
- Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. · retained source version 1:2026-08-13:current:18d90e7808b23db224cba424569b72b48ed5468ba9e0ca41b2279bf59667e6c6 ↗Source checked November 15, 2026
- Experts recommend against calcitonin-salmon for postmenopausal osteoporosis. · retained source version 1:2019-01-01:current:8f3b9e44c6e324f281a8236c3d7bf56df00bdbe4462e88459140a0784db83c49 ↗Source checked November 15, 2026
- Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells. · retained source version 1:2023-08-31:current:5af679c7fcd958931783f4ee55092945f36abe69079c2d020db5c43b0d71f46d ↗Source checked November 15, 2026
- Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds. · retained source version 1:2026-01-27:current:6486dbc996a05ed84ffa158e6c0ad63f345feec48cf58bc2d17624e6e511b1f9 ↗Source checked November 15, 2026
- Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. · retained source version 1:2018-12-17:current:71c036f770a738a815dc289288707cfb745bf0fcdd983e9dcc63adde7a667629 ↗Source checked November 15, 2026
- Fatal Interstitial Pneumonitis During Combined Degarelix, Darolutamide, and Docetaxel Therapy for Metastatic Prostate Cancer. · retained source version 1:2026-08-13:current:b35a1e4bcf506d66c521f8fa4cc5f80e65eb128079d70f2dabc1a0bcfe1a4658 ↗Source checked November 15, 2026
- Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. · retained source version 1:2022-03-31:current:6f8f704476bf17f565a97a18a8ba8ac74c19fc06c92b4007b444e16187c0ad55 ↗Source checked November 15, 2026
- First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib. · retained source version 1:2026-07-20:current:4a13c722e2089eb988f66162128597ba40ed08927e74817cceaa4bb12072a5ec ↗Source checked November 15, 2026
- Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix. · retained source version 1:2021-10-20:current:2483352fef51ba02c8a2ce2f9d4523a2fc7890644079c46264f25809fedf1e57 ↗Source checked November 15, 2026
- Formulary Drug Review: Etelcalcetide. · retained source version 1:2019-11-20:current:007471494e9fc5360ea70f0b481bb68335e37dc70168a36bd3189685e095f867 ↗Source checked November 15, 2026
- Formulary Drug Reviews: Terlipressin. · retained source version 1:2024-12-02:current:9eeb11348f9fc803ab976a29143fdcd0fae74c1d2ed669d0eefbe9d82553946b ↗Source checked November 15, 2026
- From cranial diabetes insipidus to vasopressin deficiency: terminology, tests and treatment. · retained source version 1:2026-08-31:current:b1c465af3220e3f35c2e2b3aa1155dce9b4c61fcddf56919b6923e461e9aede1 ↗Source checked November 15, 2026
- From lab to bedside: emerging clinical applications of thymosin alpha 1. · retained source version 1:2022-03-16:current:bffda92a1abc3f88971609b152f0abbfa89350ba8b2f3b400243793c62b19034 ↗Source checked November 15, 2026
- From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. · retained source version 1:2026-08-26:current:fde00fc3fe2dc90fe1c80f6879e5921d21e25bc772e4efcb20a9d61b8c2b83b6 ↗Source checked November 15, 2026
- Ganirelix acetate. · retained source version 1:2019-02-21:current:706cc62fa436536b7927a0180248bc234cfa37774d5bf5a3115adf69f3b4c9db ↗Source checked November 15, 2026
- Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'. · retained source version 1:2016-11-25:current:38b215f010b6be35ea850b6bdfe7185838b0dc9a33a77e21b46c49b2f775c5ba ↗Source checked November 15, 2026
- Ganirelix. · retained source version 1:2018-11-13:current:41ff322a2392f626f98bb8004b8952dd3df01489da2a33c340dd5b9c2d339d8a ↗Source checked November 15, 2026
- General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. · retained source version 1:2016-11-24:current:cabe956b6f715b645a6742552e38f399b337521107816fad8093c834c042fe87 ↗Source checked November 15, 2026
- Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation. · retained source version 1:2015-06-23:current:03ee99941d89cf1a6e157bf3932b3bbc1120ae0c3c7c1f90754eb1b98806aabe ↗Source checked November 15, 2026
- Goserelin ('Zoladex')--offering patients more choice in early breast cancer. · retained source version 1:2026-01-28:current:2e2f1cc96ff7fd504e005fe30d43bc24658947d4d370f7358bb6d49dd791595a ↗Source checked November 15, 2026
- Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. · retained source version 1:2019-09-06:current:50a67ff45d55e0e2ded0153173a54e9eddb25a87f04e99c06f78947d44761a8f ↗Source checked November 15, 2026
- Goserelin acetate in combination with radiotherapy for prostate cancer. · retained source version 1:2019-09-17:current:054bef8017ae042e01f3b5308d6992debf06e4d85cd1ae368bedbf6cfdc4b467 ↗Source checked November 15, 2026
- Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. · retained source version 1:2014-11-20:current:fc5f2a45c0abe958a0c1632f9ef7a3d9d2cff91d2ec77bc74499b5ebb351c5b1 ↗Source checked November 15, 2026
- Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. · retained source version 1:2018-11-13:current:a65ee9c3f1743c6b8e436719f127174b3dbeac6a911bd6f1f52bd6d97c4b947a ↗Source checked November 15, 2026
- Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells. · retained source version 1:2019-07-01:current:9eee0b05fe290549433fb51f411e3cb5df0bebee50c0a7dd4058a47abebc3f8c ↗Source checked November 15, 2026
- Growth hormone-releasing peptide-2 (GHRP-2) does not act via the human growth hormone-releasing factor receptor in GC cells. · retained source version 1:2022-07-16:current:2fee9986283ef10a157f2ebb1bb2801e822b8497af1c8e5666500728c4a7c96c ↗Source checked November 15, 2026
- Hemodynamic Management with Vasopressin for Cardiovascular Surgery. · retained source version 1:2025-01-10:current:5cd6b181a3c29227f18731ccbf65d6d31282384c116aaf17c1090001b1f169cb ↗Source checked November 15, 2026
- Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. · retained source version 1:2026-11-09:current:b73a75f3ed1968d0fac55da90714cde79932ba75a8ed52524b81dee6e22bb6a7 ↗Source checked November 15, 2026
- Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review. · retained source version 1:2023-04-01:current:8d887f39d2c9e322d53b3d02f044f8034012f5997a6e9d4fd742e62abef7957e ↗Source checked November 15, 2026
- Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds. · retained source version 1:2021-06-17:current:48afb56189b4b2b496000cb71d1282c18f06df9bdda6e5c6caef34aed7ba0a65 ↗Source checked November 15, 2026
- Hernia enlargement and pancreatitis in a patient with short bowel syndrome treated with teduglutide. · retained source version 1:2022-05-01:current:04be567715350be281b8883e2e7abb6eb551e2d9197b601b4b7a0d7b39649bd5 ↗Source checked November 15, 2026
- High-performance liquid chromatographic assay for the alpha-melanotropin[4,10] fragment analogue (Melanotan-II) in rat plasma. · retained source version 1:2019-06-29:current:ba6819f90c5012ebe907acebc7a6704838984273c29ce04aa0fd4a4252148a35 ↗Source checked November 15, 2026
- High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments. · retained source version 1:2022-12-07:current:7f7bccf7189f059712f40a37bcf47b2a1c04b46a8fb3a84d6659808f5a54ef55 ↗Source checked November 15, 2026
- How satisfactory is on-demand icatibant from the patients' perspective in real life? · retained source version 1:2022-04-18:current:a2053bc250677fa6f88698e9cdcf27570e867cfdab44b82682a8b4218049a9a6 ↗Source checked November 15, 2026
- How to Position Pasireotide LAR Treatment in Acromegaly. · retained source version 1:2020-05-05:current:780264ddff82dbaaf78e82dcbe5c7c5e7703291ebe853d3c7b9725b8cdb4fd46 ↗Source checked November 15, 2026
- Hydrophobic Tag-Assisted Scalable Synthesis of Trofinetide and Its GPE Analogues. · retained source version 1:2026-07-16:current:9105d1304fca542e3ee2043711fbee374ad7e1a2b2174df6d071482cebd10a8c ↗Source checked November 15, 2026
- Hyponatremia due to preserved non-osmotic arginine vasopressin secretion in adipsic diabetes insipidus: a case report with review of literature. · retained source version 1:2025-02-04:current:709868c7eaab852d47ed16db883a2c0b30952bf8afc6dc92a4dec1b5dba94c1c ↗Source checked November 15, 2026
- Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. · retained source version 1:2022-03-11:current:0195478181c4ff05e4c958e7233d4650106504107eb70d4b76726369102891d9 ↗Source checked November 15, 2026
- Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. · retained source version 1:2022-03-30:current:8def6900d240a2dbaf4d515cb72bf7082bf7143888152f7d5069bae4d2b947f8 ↗Source checked November 15, 2026
- Icatibant Acts as a Balanced Ligand of MRGPRX2 in Human Skin Mast Cells. · retained source version 1:2026-03-29:current:718814e022fe155d5bc3338ae230375fd963a3752e8ee336011e9750a2622d3c ↗Source checked November 15, 2026
- Icatibant as acute treatment for hereditary angioedema in adults. · retained source version 1:2017-03-10:current:bef89c88056344b571518fd380cb8a740578b625263fa08106cdd1be1c904caa ↗Source checked November 15, 2026
- Icatibant for acute hereditary angioedema attacks in pediatric patients: A systematized review. · retained source version 1:2026-06-30:current:96fe90b6eb8e95b837424210109fd6e61191ab01a9f82939abd5af48fe01ed3b ↗Source checked November 15, 2026
- Icatibant for hereditary angioedema. · retained source version 1:2025-10-22:current:185eb56af1c1799fe5d4c1e23b109c1727a6f20e8536d2d53c89a32e97ccbd45 ↗Source checked November 15, 2026
- Icatibant for the treatment of hereditary angioedema. · retained source version 1:2017-11-16:current:40bc755b4ca5b4e5589023f1ebb3f7dbe3a3ef20c47ba1428afe49c5b9ca73ef ↗Source checked November 15, 2026
- Icatibant in hereditary angioedema: news and challenges. · retained source version 1:2013-11-21:current:cb905e81ebe125e87d2f0f3ddc04cb9414d5a0224ba3d2d40e73c50b054d3ea1 ↗Source checked November 15, 2026
- Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report. · retained source version 1:2022-12-07:current:04c2448d3d782f2dbad8cb143a438b3eb1c7323c3f2f12251251f07df94a38b0 ↗Source checked November 15, 2026
- Icatibant in viral infections. · retained source version 1:2026-01-27:current:0019f66a21e3f34e79e7772a19d49d9f5396c9c2658a96296b46b9160cb1f52c ↗Source checked November 15, 2026
- Icatibant Use During Pregnancy: A South African Case Series. · retained source version 1:2025-12-16:current:b3374388215a9bc82bbb5b104122acb9d21b4b6d365e4addb648b402505e3553 ↗Source checked November 15, 2026
- Icatibant: HOE 140, JE 049, JE049. · retained source version 1:2018-10-25:current:59b2d39c5a902fdf9f2cce64ee38e4fc0d644098c6a59e8ec4bed122b4b066f9 ↗Source checked November 15, 2026
- Icatibant: HOE 140, JE 049, JE049. · retained source version 1:2018-10-25:current:5ae456c1c682d0773e7d865add704e2fd4de5693b18c6ff65c83f482d79e40e9 ↗Source checked November 15, 2026
- Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. · retained source version 1:2019-12-10:current:35df72d72c5530d0ec1f0b2996d14c233f54e761f5cbf6d2196c6b30c061e10f ↗Source checked November 15, 2026
- Identification and quantification of the doping agent GHRP-2 in seized unlabelled vials by NMR and MS: a case-report. · retained source version 1:2019-12-10:current:3b38f2090b3039b886fb23f88de7106a699a745dfffc85f21a6b05f4cf983bb5 ↗Source checked November 15, 2026
- Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS. · retained source version 1:2021-06-17:current:ce8bc2a6a59ba4112512b94477c781c136571a4e1c07d6812e616d1425a512e7 ↗Source checked November 15, 2026
- Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. · retained source version 1:2016-11-25:current:35e8e7faf59cc76eb467fed0a66deb73c63df2f9a5ce1ef902789285ec25c687 ↗Source checked November 15, 2026
- Immature rat seminal vesicles show histomorphological and ultrastructural alterations following treatment with kisspeptin-10. · retained source version 1:2024-03-18:current:44348ec533989020d5c0f4def5df9901a937d649a35c58b382ec2c5bc2ee8052 ↗Source checked November 15, 2026
- Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections. · retained source version 1:2023-11-12:current:ad0c9d1b303f5ecb21580870195633a344d3b35ddc4728d39547174826b8d741 ↗Source checked November 15, 2026
- Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review. · retained source version 1:2026-08-29:current:5302288557ae44f097e1e69ca35cb3e3b9a66df8d0e44babc1efa8b2551fd50d ↗Source checked November 15, 2026
- Impurities identification and quantification for calcitonin salmon by liquid chromatography-high resolution mass spectrometry. · retained source version 1:2021-03-29:current:ebc1db2b12289e6e30b7d687ae80dce772750b4a37e7c1d493f38d89238f3ef3 ↗Source checked November 15, 2026
- In vitro and in vivo human metabolism of degarelix, a gonadotropin-releasing hormone receptor blocker. · retained source version 1:2025-02-12:current:493aea957144003f58abc05f836ab02dcee3e0619028ceb66b3df23ea1465eef ↗Source checked November 15, 2026
- In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450. · retained source version 1:2014-11-20:current:16a2f8e09d19f99064417912fd2100a558bf5da31b6979bf8b7dc3f57391a138 ↗Source checked November 15, 2026
- In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone ([(18)F]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist. · retained source version 1:2021-10-20:current:60ed16881a18353ebc71ab7a72a08e6e99187a534ec100337a18c0cb638abaa7 ↗Source checked November 15, 2026
- In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant. · retained source version 1:2026-01-27:current:bf2d7f8faf9adfa71ff8429f196cdcef05271dda4cb747d55dffedc65a20f2ce ↗Source checked November 15, 2026
- Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. · retained source version 1:2024-08-24:current:df6d355e29a9bb9e1a2790b090764e2bb011cf65c2d398dc323360305a2bfe51 ↗Source checked November 15, 2026
- Influence of neurokinin B, dynorphin A and kisspeptin-10 on in vitro gonadotropin secretion by anterior pituitary cells isolated from pubescent ewes. · retained source version 1:2025-03-29:current:138ae03e63a5ba17c78177ac310f633e41939d57d104e4352ecc1711e3075016 ↗Source checked November 15, 2026
- Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide. · retained source version 1:2019-01-09:current:67ae88566f3fd47ff3c4de6896464fba48ad525cf7fb17617ecf0ba7f1f10546 ↗Source checked November 15, 2026
- Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. · retained source version 1:2025-04-28:current:b639a6ed9cfe28bd523fd2aacdeb6f23559b416d3739d21e90494762608f6d76 ↗Source checked November 15, 2026
- International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance). · retained source version 1:2026-11-01:current:62cb7f7ca094b3dbaffa517f3ec39b5a190765080a231be4ed731df9a7c63303 ↗Source checked November 15, 2026
- Investigation of the clinical significance of the growth hormone-releasing peptide-2 test for the diagnosis of secondary adrenal failure. · retained source version 1:2022-03-21:current:822ad5fc3e5b910da0554557d1db2a9136d01f8baf73cf788214322dc9c0e795 ↗Source checked November 15, 2026
- Investigation of the GnRH antagonist degarelix isomerization in biological matrices. · retained source version 1:2023-07-19:current:f0183ac2751ab7f21171bb646da537bfc46c0d5d04518783ac6c612481519a2a ↗Source checked November 15, 2026
- Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis. · retained source version 1:2022-04-01:current:d895045f9899466c91d7290e7f5558ee273ec9c6551aae6fe79a8f4d48a9ffe9 ↗Source checked November 15, 2026
- Is it time to switch to bivalirudin for ECMO anticoagulation? · retained source version 1:2023-09-07:current:d66cc0ecbc41a2aa9b601b2cfdd7c070ec582207c3068a088f0f5124a6f46bd1 ↗Source checked November 15, 2026
- Kisspeptin-10 and the G protein-coupled receptor 54 are differentially expressed in the canine pregnant uterus and trophoblast cells. · retained source version 1:2017-09-21:current:676e90dd63a5c039eebc0601dae0e8a392829bf95f380016bc9b7d120e2db095 ↗Source checked November 15, 2026
- Kisspeptin-10 facilitates a plasma membrane-driven calcium oscillator in gonadotropin-releasing hormone-1 neurons. · retained source version 1:2018-11-13:current:9e006b9a2c3d96c59646228e4b6283ce3722dd77698e47b020d011049745da69 ↗Source checked November 15, 2026
- Kisspeptin-10 Preserves the Blood-Brain Barrier's Integrity Post-Stroke by Augmenting Claudin-10 Expression. · retained source version 1:2026-06-28:current:75d3bd56570edd0e842084cb45d1fe0fbef834eb70c68de0c4ea01107014d772 ↗Source checked November 15, 2026
- Kisspeptin-10 treatment generated specific GnRH expression in cells differentiated from rhesus monkey derived Lyon NSCs. · retained source version 1:2018-09-05:current:b7ed553457aac85dd716b7ad8a6f1570e21c0239fa2623c0229a1e775371d858 ↗Source checked November 15, 2026
- Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. · retained source version 1:2025-04-28:current:f8276733103c11208a9ad634a14192fab92805dc2adca3d1f5de1b38fdd3171c ↗Source checked November 15, 2026
- LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. · retained source version 1:2025-05-29:current:68333010a5f9c0fb52a4be8e1485a3bab89f21b4bb0e93f39774f10c59e640f1 ↗Source checked November 15, 2026
- Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. · retained source version 1:2026-02-23:current:801abd8a5d1adeacc2080d8db425bafcf1c1b4b732e5a2d3e4028077f836ba0a ↗Source checked November 15, 2026
- Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study. · retained source version 1:2026-02-23:current:873d567165e899cd1c0a6ee074da087b43661135d8d4722e3d7ec16606a35904 ↗Source checked November 15, 2026
- LL-37-MRGPRX2-Mast Cell Signaling in Rosacea: Current Evidence and Directions for Human Studies. · retained source version 1:2026-10-13:current:14dadcde95e28d1ac56f292c880d87189d641acf965a06ee12a3a8171e29f789 ↗Source checked November 15, 2026
- LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity. · retained source version 1:2025-01-07:current:f628957ee0d106997d53076ac110455c94e27dc6b57ceb1e6d2ae27bce2f78cc ↗Source checked November 15, 2026
- LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease. · retained source version 1:2026-09-21:current:e5cd8a2a860bb78fa8ee55889617890d9a1c5edebe375d1d8ec5a18f3240d3e7 ↗Source checked November 15, 2026
- LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity. · retained source version 1:2022-12-07:current:e3fe5d120c911453c399ed114794389860b8b25eb688e20b854a21a3f2cdcad3 ↗Source checked November 15, 2026
- LL-37: Structures, Antimicrobial Activity, and Influence on Amyloid-Related Diseases. · retained source version 1:2026-04-16:current:641e5140165dec1d7cae3ce25b4c090f2cdfaabe718b22c6406fe9f3e21b085d ↗Source checked November 15, 2026
- Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. · retained source version 1:2018-11-30:current:91f1efe414b2a1972821fa2a93c5fb3861405a19d61f559cd5ba9bad54542501 ↗Source checked November 15, 2026
- Long-acting triptorelin for the treatment of endometriosis. · retained source version 1:2019-08-22:current:be0026a8dcbf98b7f2a620756388796307c1d8172990e98e346089e74bbf449b ↗Source checked November 15, 2026
- Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience. · retained source version 1:2014-09-18:current:4784d3e1d63ed90eb9beb044acadba48c6e707c01609fe9ffa49e86a2144c362 ↗Source checked November 15, 2026
- Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences. · retained source version 1:2024-06-01:current:fa30890b18a5294dee26ce407209bb756c08fb74560057f5b7df4e3ae8aa4706 ↗Source checked November 15, 2026
- Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome. · retained source version 1:2023-06-16:current:fdc802a8e1c2a285a2ed58994efbb11f9afb7c23bada4dd9e5d2735bf115e369 ↗Source checked November 15, 2026
- Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study. · retained source version 1:2026-10-31:current:68727c48629ef71cfc7df42acdeaf5342491122ce3896f4df1f1411e3688a3f0 ↗Source checked November 15, 2026
- Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome. · retained source version 1:2024-05-11:current:301b0cd6cf5b8ede0bd10b9835c293184176916272c546694a651d3ad79040ab ↗Source checked November 15, 2026
- Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. · retained source version 1:2018-11-30:current:8d7cf5cfcd948a6556170af0cf9a2b20840079269235c2a6dbc9fc2db24c84c3 ↗Source checked November 15, 2026
- Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. · retained source version 1:2019-07-14:current:f19c6aa3c5f5fc588921856a26f30dc90a02ff70ffa7ad294ae28aea6b01e53d ↗Source checked November 15, 2026
- Management of a patient with locally advanced prostate cancer with degarelix: a case report. · retained source version 1:2013-06-20:current:0e1c6328707218feaa7278ed451be100804209d47e8d886a9e95aa9c4b51f54b ↗Source checked November 15, 2026
- Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants. · retained source version 1:2026-10-16:current:44a31b478ca1b42504373c04a3fea7650bace03ab75ef12ab9b4be11e4b1da4b ↗Source checked November 15, 2026
- Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review. · retained source version 1:2024-07-30:current:050569a67f687f4a9b29e9f8ce23626f2a77f7a250cf60e26848274c28dc5f49 ↗Source checked November 15, 2026
- Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks. · retained source version 1:2021-09-03:current:a0dba0ed0db29fd9354e52e967edf206b44d5a2115bfbbb81617592f1090c781 ↗Source checked November 15, 2026
- Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. · retained source version 1:2026-01-28:current:ca4e23402ec85f330150d1f2aa45a1f1b4fc0d63f6cd63bf59d096c0db75cfa3 ↗Source checked November 15, 2026
- Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. · retained source version 1:2026-01-27:current:b069c6037257e348a830f298fe12a52d9c5ef57c36ee9d3b53e9530b5e3e45e6 ↗Source checked November 15, 2026
- Management Patterns of Teduglutide Use in Short Bowel Syndrome: A Survey of 70 Healthcare Professionals. · retained source version 1:2024-11-16:current:61a55d2e3467bdae573589054a6c61343fa2fa85c5e627c961a75f3d803e1add ↗Source checked November 15, 2026
- Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives. · retained source version 1:2026-01-16:current:b7132ceeb4f824db8522bf023e91e93e95685165105fe95833c921d4f052961b ↗Source checked November 15, 2026
- Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. · retained source version 1:2024-03-13:current:7f42ac2f90a750bfb72d3199588c250899e4a218fd2a1d9651f4cdf6db213a52 ↗Source checked November 15, 2026
- Manifestation of morphea in a patient with myasthenia gravis under therapy with zilucoplan. · retained source version 1:2026-02-07:current:6885b5438030d3f009c5350bea2bd24c3ae9bac1610818605ace02139a7d1b75 ↗Source checked November 15, 2026
- Mapping Trofinetide Polypharmacology in Rett Syndrome: A Multi-Stage Computational Analysis. · retained source version 1:2026-08-13:current:567c9f9ae050e9c047e4883452890a26bf46124687c391a4570081a120925d54 ↗Source checked November 15, 2026
- Maternal Kisspeptin-10 Treatment Partially Rescues Fetal and Postnatal Cardiac Programming Disrupted by Maternal Hypothyroidism. · retained source version 1:2026-10-16:current:43ee95908123a1d40a653b94f0399136828f6f9d06649c9aaea2da6fdba12ed5 ↗Source checked November 15, 2026
- Maternal plasma kisspeptin-10 level in preeclamptic pregnant women and its relation in changing their reproductive hormones. · retained source version 1:2021-01-15:current:a7e04e28fb9f399282afc97fd3aabcb743fd16d337bc8b38778cdf2788dcefde ↗Source checked November 15, 2026
- Measurement of ionized calcium with a point-of-care ionometer during etelcalcetide therapy. · retained source version 1:2026-09-26:current:2836fa1225a8767e1d5d8e5f7cdaa32d68c4fa6de6ae594c67cc5dd1a7fa1b0a ↗Source checked November 15, 2026
- Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. · retained source version 1:2019-11-04:current:a98ac9bb6144a828b4aa47ec0e3211db7a135f6494ec31fd9a62e0a9cc8f9224 ↗Source checked November 15, 2026
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. · retained source version 1:2022-02-15:current:c13661b39e7b667ffa36d866c4f939c6f57d14281f63b1377a0fbca65732008f ↗Source checked November 15, 2026
- Melanotan II: a possible cause of renal infarction: review of the literature and case report. · retained source version 1:2021-06-21:current:c55812464c839830fa26c4e9d21b1ba6c5ab1434377b1bf8174a557d1bce963c ↗Source checked November 15, 2026
- Meta-Analysis Comparing Bivalirudin Versus. Unfractionated Heparin in Adult Patients With Extracorporeal Membrane Oxygenation. · retained source version 1:2026-11-09:current:9d6aa461370ec5361e6574bbddb2eb7d53f1d8398e84c2bf28e806185874f8cd ↗Source checked November 15, 2026
- Meta-analysis of bivalirudin versus heparin in transradial coronary interventions. · retained source version 1:2021-08-09:current:6149fb3e80dd6e61f07f8ac429b84ab5872e0c3438b7825a160e9cb35d4a9fda ↗Source checked November 15, 2026
- Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey. · retained source version 1:2025-02-12:current:4344172fb21ca80539cde28e2f249bb17476dccd58e6f8959cb49b4ba9234154 ↗Source checked November 15, 2026
- Modification of the in vitro release profile of Cetrorelix by complexation with biophilic partners. · retained source version 1:2019-11-11:current:ef39ba1fb2cb3f874fcc2917d485e0c27cde68b183f130ee0ea9c913b4560aa5 ↗Source checked November 15, 2026
- Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix. · retained source version 1:2024-03-26:current:a04c34ec8affcc5a70d630e243b27e6c98becb38e6b0759b889392728a751c8d ↗Source checked November 15, 2026
- Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin. · retained source version 1:2026-01-27:current:bafbfd031e07299d01d17c8ee8db25f2777e29c42645d1f31c15f9449763453a ↗Source checked November 15, 2026
- MprF-mediated daptomycin resistance. · retained source version 1:2019-11-21:current:2cc8895a55ee3935e0925d49cd63d12fa33debafb22c2dd1071df55edbde7112 ↗Source checked November 15, 2026
- Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. · retained source version 1:2016-11-25:current:5b1308f95d8d0329c90df5bb2f7d7a87c3e979085db3e7f78eb2c2bff3403bcf ↗Source checked November 15, 2026
- Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. · retained source version 1:2026-01-28:current:88b56133875bb1ef7f68b2b2664a73257ac87a5079a36948f201ff04f1d67019 ↗Source checked November 15, 2026
- Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial. · retained source version 1:2026-09-14:current:69d068216aa50f316e5953d91bcee4c29ce394f8061dde437de0357d548d4d3e ↗Source checked November 15, 2026
- New Drugs Update: Finerenone, Difelikefalin, and Avacopan. · retained source version 1:2026-11-09:current:19137ebabf3c5a83d3e4540f522ef6c5bcfd6b24f14c95e4540b073548dd1914 ↗Source checked November 15, 2026
- New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model. · retained source version 1:2026-01-27:current:ad0eccfae894ff15474480ade22bbdabaf61d287e1ea0ba04bef6ab864eb05d9 ↗Source checked November 15, 2026
- New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. · retained source version 1:2021-06-04:current:3b22b6b34abb19e477faf26c847c0a1835480b56862f23a59d1e801ab61f775c ↗Source checked November 15, 2026
- Noradrenaline or terlipressin for hepatorenal syndrome? · retained source version 1:2018-12-02:current:9fb214214140ae90b3eb0f6ee35655fd7966de4778eaca369210d3a7e4fb065e ↗Source checked November 15, 2026
- Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. · retained source version 1:2026-01-28:current:d9d8c3d4d80a04e7a566b0b44590cb7fb87376364f14dc924bc4a028bf52e79a ↗Source checked November 15, 2026
- Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. · retained source version 1:2024-12-19:current:ecd52517ef83fe914216e052d9d9d87d2547ae3e39549398bc310ed5dfc7f1f4 ↗Source checked November 15, 2026
- Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia. · retained source version 1:2026-10-07:current:8566f9c150bed53310c87f7b27359ca29467d8e4c4c718afbddd0984cd8d27f6 ↗Source checked November 15, 2026
- On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse. · retained source version 1:2021-10-28:current:21d77567dd0c4ac4c0e528b19357a145a74d440d385b530fd7b52c85a3b9e41e ↗Source checked November 15, 2026
- On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation. · retained source version 1:2026-08-28:current:329cb878448588e6d2bb0bf5e340473ff0c96cd854bf108c1d6a53d084a8f85f ↗Source checked November 15, 2026
- Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide. · retained source version 1:2022-04-10:current:68f47206e28d91dfe0dbdb1ed6d817292d4c3d835394681363824478eb13b753 ↗Source checked November 15, 2026
- Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions. · retained source version 1:2026-11-05:current:6681f7c6d7abfd231c4f43d6a8d9ed8bed5adce8fdfb079ffeebd1253370cd91 ↗Source checked November 15, 2026
- Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial. · retained source version 1:2026-10-01:current:7bfe14d7c30c033cf8252740f83c0dad532329f44e56ab64ccf2a64f5b458390 ↗Source checked November 15, 2026
- Palopegteriparatide therapy for hypoparathyroidism: targeting the PTH receptor rouses the sleeping skeleton. · retained source version 1:2026-09-27:current:1de91bfcd2448619830e88940a69d9cbbfe0921aa8465096ba3b819042c35cbd ↗Source checked November 15, 2026
- Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update. · retained source version 1:2026-08-20:current:9de6515f2d507e0054f5710827fbc51cbae7b7992f069527cd1e8009ca059d3f ↗Source checked November 15, 2026
- Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults. · retained source version 1:2026-10-24:current:0a8c8d3a1a7372c3808ddc492482d6435ec8d3996a580ae1f1e850e5e01d5348 ↗Source checked November 15, 2026
- Palopegteriparatide. · retained source version 1:2025-01-06:current:00b610d803a4af5099cdd61d87910613bd62ee2b2cac8a5c4ce4059ddeade246 ↗Source checked November 15, 2026
- Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. · retained source version 1:2024-08-01:current:c6888daf7bd0a6a4ca340a3b96cdef9be4eb8fc53e4115190aac78882035bdae ↗Source checked November 15, 2026
- Parsabiv Could Be Pricey Addition In Care for CKD, ESRD Patients. · retained source version 1:2019-05-23:current:6392fb4e3accd98a658594da6601a962c7a44febafcb77d8dd6535fa1f0f49e2 ↗Source checked November 15, 2026
- Pasireoride (Signifor) for Cushing's disease. · retained source version 1:2014-11-20:current:aa5b029d1e1e2680128ce2e1cf1f1e4b1a522fc3ce3843fad46d3832ae323d28 ↗Source checked November 15, 2026
- Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. · retained source version 1:2022-03-15:current:d1ae93e70c548af83194eb4ae280d23c54e8b5d971f83b9332567d5aa536c402 ↗Source checked November 15, 2026
- Pasireotide and mifepristone: new options in the medical management of Cushing's disease. · retained source version 1:2021-02-04:current:2e5e3acd71e37c0b5b866aadff8cf8dbc742ca5633ea74d3726a4af98d3f1830 ↗Source checked November 15, 2026
- Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature. · retained source version 1:2023-11-05:current:9a90af70e9e8bfbfc5452e2694cb0b0583da5017669a171872df67e562ec83ad ↗Source checked November 15, 2026
- Pasireotide for the treatment of acromegaly. · retained source version 1:2022-03-10:current:03de4b0fffb8c7d4cddf99242d37a130a79d710b18b8f2d75b6965d36b2de07f ↗Source checked November 15, 2026
- Pasireotide for the treatment of Cushing's disease. · retained source version 1:2014-11-20:current:36ed7cac2f32fcde87d37dcc893d75c8b8a6bcadd8c6a7fcb673ce1521c1bc5f ↗Source checked November 15, 2026
- Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial. · retained source version 1:2022-03-09:current:61cec8f8ab4fab0a961a247379f611dbbcf68c601da45902af9017bf84a67652 ↗Source checked November 15, 2026
- Pasireotide-LAR and pegvisomant combination in resistant acromegaly: a case series of predominantly mammosomatotroph adenomas. · retained source version 1:2026-10-31:current:0ea9a68b7b8ff277d2b491dd26927c975a97729c2ea2323b3f81cb955a6a7eae ↗Source checked November 15, 2026
- Pasireotide: a review of its use in Cushing's disease. · retained source version 1:2026-10-11:current:b5eefefc81f19152c7deca52760c5911a329d61a6202b3b86542caf6e19765ff ↗Source checked November 15, 2026
- Pathophysiology of COVID-19: A Post Hoc Analysis of the ICAT-COVID Clinical Trial of the Bradykinin Antagonist Icatibant. · retained source version 1:2025-06-27:current:faaafa5babc09af860e131d946bd26009d372116b3e0808c00e907998ea87ec8 ↗Source checked November 15, 2026
- Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands. · retained source version 1:2022-04-30:current:ecb2eb840f9e4cc5e056ab35bb29b20d1fee3e4e76b8b34ebb142ce28555deb9 ↗Source checked November 15, 2026
- Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. · retained source version 1:2018-11-13:current:dd270985557e2f3668d9b9b283ee94ceb6499c269b48031edf4305e46a995ae0 ↗Source checked November 15, 2026
- Pediatric Central Diabetes Insipidus due to Arginine Vasopressin Deficiency in the Perianesthetic Period. · retained source version 1:2026-06-26:current:43d7834aeee13f57b4e851ab6cd7c24990d22458f03f246102e5d0de0f7e52a7 ↗Source checked November 15, 2026
- Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. · retained source version 1:2026-09-16:current:d6d4471b5d34e3f4eafe6fce2b2da796ab83f8a51f6bd6736cca61756914386b ↗Source checked November 15, 2026
- Performance evaluation of antimicrobial peptide ll-37 and hepcidin and β-defensin-2 secreted by mesenchymal stem cells. · retained source version 1:2024-07-21:current:06a7c6bc7fab6882c181e081b6a363922be9c24dc6d4b81da237efab3a52d345 ↗Source checked November 15, 2026
- Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. · retained source version 1:2020-05-14:current:ed409cd8283e20ea285c63918d098fd65431ea25e2839f56a6dd50c552b92e1b ↗Source checked November 15, 2026
- Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism. · retained source version 1:2026-08-13:current:28ffc0c1ea19b29afcfde16d1de3da83bdd02fb208f6768360a76e2a8f619e3c ↗Source checked November 15, 2026
- Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis of CTB-001, a Recently Developed Generic of Bivalirudin. · retained source version 1:2020-02-25:current:85a7aceae8e5d2b120283986585d68371549eaee2efd517c923461fb8443e79b ↗Source checked November 15, 2026
- Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. · retained source version 1:2019-09-22:current:c1e0f2c0c4a4436ae2e3e160a4d14ffb49f94ce89b525efef3515177b2117403 ↗Source checked November 15, 2026
- Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. · retained source version 1:2016-11-24:current:07dee7513491a421b4e751ed931c73d444f0dfb94727dfc715712ea1f618bec1 ↗Source checked November 15, 2026
- Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. · retained source version 1:2016-11-24:current:8767112dcd6ea02ea892946b85c5e9c2d8c9409aabe48adb8ea011dbb0f22b77 ↗Source checked November 15, 2026
- Pharmacological mechanisms and clinical evidence of vasopressin, steroids, and epinephrine triple therapy in in-hospital cardiac arrest. · retained source version 1:2026-08-19:current:40ac61a51fdea172b5ecedc53e13fd44c9d52fcbb99706c90aec642af2a7c567 ↗Source checked November 15, 2026
- Phase 2 Trial of Difelikefalin in Notalgia Paresthetica. · retained source version 1:2026-05-18:current:482b9f86abf3e8c9746c5d765626f6d98876225f759f98d4db575b32ccfd07b0 ↗Source checked November 15, 2026
- Phase I study of eptifibatide in patients with sickle cell anaemia. · retained source version 1:2018-12-01:current:ff1ce28ff3a39bb1aa4b9524ece3ec936f2a04d23301f28d69c3b5cdb82bc16e ↗Source checked November 15, 2026
- Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. · retained source version 1:2021-02-16:current:17864179dc69980f4ec860ac00c9bcaec6d7abf9e8a02af34106272b75fcab50 ↗Source checked November 15, 2026
- Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. · retained source version 1:2019-02-15:current:75d4e348ac5176a64779b7e9240abc893ca3893ebe168cf7b3c57e9759b57d59 ↗Source checked November 15, 2026
- Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. · retained source version 1:2019-08-27:current:4e66d73cafb5b7c676f92d5a82d1ef51604cbd5dbeaf43b872bc6cfde2f5581b ↗Source checked November 15, 2026
- Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. · retained source version 1:2022-03-31:current:593971726c444be7ed98898f746639c6da2d07def2ba1b53a9bffdd2938afb02 ↗Source checked November 15, 2026
- Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer. · retained source version 1:2026-03-05:current:c69ea7ac4f0132b023a8166d3acd70a3a238a750fa73db604f708db279db146a ↗Source checked November 15, 2026
- Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. · retained source version 1:2022-03-16:current:2dc1b8a5d512391ca0ecd7590e053036ebdcca389299db2f42d462a88e4644e9 ↗Source checked November 15, 2026
- Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. · retained source version 1:2024-08-16:current:db389e4e0664492de32fbc3172eb27d1942e47c053732b0e700a8e87b92de717 ↗Source checked November 15, 2026
- Phenotypic drug discovery: a case for thymosin alpha-1. · retained source version 1:2024-06-22:current:1868701eb2fd1a0c736c5b24e4c20c1b9a6929abbba785eb518a23d7ef017fb7 ↗Source checked November 15, 2026
- Physiologically based pharmacokinetic model for pralmorelin hydrochloride in rats. · retained source version 1:2025-02-12:current:355191940fe964dca114595a612f69c5ae39d216412752bc659e1a4f5f026e0b ↗Source checked November 15, 2026
- Pituitary acting drugs: cabergoline and pasireotide. · retained source version 1:2026-10-30:current:736d5b46831312cff35752a3c1b4748cc951a8230e26bd60496eac66a5ace105 ↗Source checked November 15, 2026
- Plasma concentrations of peptide hormones: Unrealistic levels of vasopressin (AVP), oxytocin (OXT), and brain natriuretic peptide (BNP). · retained source version 1:2026-01-30:current:163569bc281b6c50393b0fb1d476ab1496bbc3c5311453337139303bbf538836 ↗Source checked November 15, 2026